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Microdialysis is a popular method for real-time monitoring of neurotransmitters in the 
brain, applicable for a variety of research areas. Nonetheless, insertion of the probe into the brain 
tissue results in a penetration injury that triggers ischemia, activates astrocytes and microglia, 
and damages neurons in the surrounding area. This insertion injury significantly affects the 
ability of the microdialysis probe to collect samples from the surrounding tissue, a consequence 
that is further exacerbated with time. Incorporating dexamethasone, a glucocorticoid anti-
inflammatory steroid, into the microdialysis perfusion fluid is a simple yet effective strategy for 
mitigating the probe insertion injury. The benefits of dexamethasone retrodialysis for long-term 
sampling from the rat brain are presented herein. 
First, stimulated dopamine release was monitored with fast scan cyclic voltammetry next 
to and at the outlet of microdialysis probes at 4 hours, 24 hours, and 5 days after probe insertion 
into the rat striatum. Perfusing the microdialysis probe with dexamethasone and allowing the 
tissue 5 days to recover reinstated normal evoked dopamine activity adjacent to the probe. This 
provided quantitative agreement between responses measured directly in the striatal tissue and 
those measured at the probe outlet.  
Second, transient changes in K+ and glucose were monitored in the rat cortex following 
the induction of spreading depolarization at 2 hours, 5 days, and 10 days after probe insertion. At 
all three time points the retrodialysis of dexamethasone improved the detection of K+ and 
glucose transients following spreading depolarization. When microdialysis probes were 
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implanted for 5 days without dexamethasone the glucose responses became essentially 
undetectable, however 5 days of dexamethasone retrodialysis preserved consistent glucose 
responses at both 5 and 10 days after probe insertion. For the 10 day study dexamethasone was 
removed from the perfusion fluid on day 5, showing the benefits of dexamethasone outlast the 
retrodialysis itself.   
The significance of enhancing microdialysis through anti-inflammatory mitigation 
strategies extends beyond the analytes and conditions investigated thus far. The ability to 
accurately and reproducibly quantify neurochemicals days after microdialysis probe implantation 
is invaluable and will aid in improving our understanding of the complex chemical events 
occurring in the brain. 
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1.0  INTRODUCTION 
1.1 MICRODIALYSIS 
Microdialysis is a powerful technique with numerous benefits and advantages for 
intracranial chemical monitoring in both animal models and human patients.1-7 Implanting a 
microdialysis probe into the brain tissue allows investigators to monitor in vivo chemical 
changes occurring in real time. The samples collected with the probe are compatible with a 
variety of highly sensitive and selective analytical methods such as high-performance liquid 
chromatography, capillary electrophoresis, electrochemical sensors and mass spectrometry.8-13 
This versatile technique is commonly used in studies of brain functions, neurological disorders, 
behavior and monitoring during neurointensive care.1, 4, 14-17  
A microdialysis probe is constructed by connecting inlet and outlet tubing to a 
semipermeable membrane. The probe is perfused with a solution, typically artificial 
cerebrospinal fluid (aCSF), and diffusion across the membrane allows the collection of any 
molecule below the molecular weight cutoff of the membrane. Adding drugs or other compounds 
to the perfusate provides a localized delivery to the tissue around the probe, a process known as 
retrodialysis.  
The samples collected by the probe, known as the dialysate, will contain a lower analyte 
concentration (Cout) when compared to the external environment (Cext). The probe recovery of a 
specific analyte is defined as a ratio of Cout/Cext. Probe recovery is influenced by several factors 
including the flow rate, temperature, diffusion and the active sampling area of probe’s 
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membrane.3 Due to the environmental differences affecting diffusion, such as tortuosity and 
uptake, it has been established that in vitro calibrations based on the probe recovery are not 
suitable for in vivo analysis.18 While several in vivo calibrations have been developed,19-21 they 
are limited by the tissue response to the probe insertion. This response creates a zone of 
abnormal tissue and disrupted neurochemical activity surrounding the microdialysis probe.22-24  
1.2 TISSUE RESPONSE TO PROBE IMPLANTATION 
Although microdialysis is a well-established technique, one drawback is that insertion of 
the probe into living brain tissue results in a penetration injury and tissue response.22-35 Inserting 
the probe disrupts the blood-brain barrier and activates microglia within minutes.32 The 
penetration injury develops over time with additional signs of tissue disruption including 
ischemia, astrocyte activation, and neuronal damage in the vicinity of the probe track.25-31, 33-35  
Since microdialysis samples from the tissue surrounding the probe, the penetration injury 
results in the samples being obtained from tissue in an abnormal state. This complicates data 
interpretation and limits the capabilities of microdialysis. The tissue response to the foreign 
object develops over time which in turn creates an instability in microdialysis measurements.36-40 
To account for this many microdialysis studies are performed with a careful time interval 
between probe insertion and sample collection and often do not sample from the probe for more 
than a few hours or days.3, 41  
The penetration injury is not unique to microdialysis, as the tissue response also affects 
other devices used for intracranial monitoring.42-44 It is important to note there is no indication 
that the penetration injury adversely affects the subject’s overall brain function or behavior. 
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Microdialysis is well tolerated by both animal models and human patients. The significance of 
the penetration injury is its impact on the ability of the microdialysis probe to provide an 
accurate report of the chemical events occurring in the brain.  
1.2.1 Dexamethasone retrodialysis 
The work detailed herein describes the benefits of utilizing dexamethasone (DEX) 
retrodialysis to mitigate the penetration injury. Dexamethasone, an anti-inflammatory and 
immunosuppressant glucocorticoid, has been used with both microdialysis and neuroprosthetic 
devices to suppress the tissue response to the foreign object and enhance long-term sampling.31-
35, 45-47 Incorporating DEX into the microdialysis perfusion fluid is a simple yet effective strategy 
that reduces ischemia, suppresses glial cell activation, and protects neurons and neuronal 
terminals in the vicinity of microdialysis probes.31-35 Using retrodialysis provides a localized 
delivery method that allows for careful control over the dose and duration of DEX provided. 
1.3 DOPAMINE MICRODIALYIS AND DETECTION WITH FAST SCAN CYCLIC 
VOLTAMMETRY 
Dopamine is one of the analytes commonly sampled with microdialysis. Dopamine is an 
important neurotransmitter with numerous roles in normal brain function and it is also involved 
in a variety of disorders including substance abuse, schizophrenia, and Parkinson’s disease.48-51 
When triggered by an action potential dopamine is released from vesicles within a neuron into 
the extracellular space where it can be measured with microdialysis. Once it is released 
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dopamine comes into contact with both receptors and transporters that regulate the extracellular 
concentration of dopamine.52, 53 When dopamine binds to presynaptic D2 autoreceptors it serves 
as an inhibitory mechanism to decrease further dopamine release. The extracellular concentration 
of dopamine is also regulated by uptake through the dopamine transporter protein (DAT).  
Along with microdialysis, fast scan cyclic voltammetry (FSCV) is another method 
commonly used for studying dopamine in vivo.53-55 This technique involves applying a potential 
to a carbon fiber microelectrode and measuring the changes in current from the oxidation and 
reduction between dopamine and dopamine o-quinone. Applying a waveform that scans at 
400 V/s from the rest potential of  0 V to 1 V, then to -0.5 V, and back to the resting potential 
(vs. Ag/AgCl) can selectively measure changes in dopamine with high temporal resolution. This 
high scan rate produces a background nonfaradaic charging current, therefore requiring 
background subtraction to identify the faradaic current from the oxidation and reduction of 
dopamine.56   
1.4 VOLTAMMETRY NEXT TO AND AT THE OUTLET OF THE 
MICRODIALYSIS PROBE 
To understand the impact of the probe insertion injury, voltammetry has been used to 
measure dopamine next to the microdialysis probe. This method involves measuring stimulated 
dopamine release with FSCV before and after implanting a microdialysis probe into the striatum 
of an anesthetized rat. The carbon fiber microelectrode is ideal for this comparison as its small 
diameter, 7 µm, results in minimal tissue disruption in comparison to the 300 µm diameter of the 
microdialysis probe. Within hours of implanting a microdialysis probe, the evoked dopamine 
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response in the tissue next to the probe is significantly decreased.24, 33-35, 40, 57 The impact of the 
penetration injury is dependent on the distance between the microelectrode and probe, forming a 
decreasing gradient of evoked dopamine the closer the microelectrode is positioned to the 
probe.24 The gradient of release is still present when the sampling time is extended beyond acute, 
4 h, studies.34, 35, 40 The dopamine terminals around the probe survive the implantation, but are 
suppressed, showing the decrease in signal is not from the terminals being completely destroyed, 
but remaining in a perturbed state.33, 57 
The gradient of responses observed around the microdialysis probe leads to the question, 
how well do the samples collected with the probe represent normal, undisturbed tissue? 
Microdialysis studies do not typically use an additional technique to sample from the tissue next 
to the probe, therefore it is important to correlate the responses next to the probe to those 
obtained at the probe outlet.23, 34, 35, 40, 58 Carbon fiber microelectrodes were placed next to and at 
the outlet of microdialysis probes for the measurement of electrically evoked release of striatal 
dopamine. In most cases, evoked release was undetectable at the probe outlet without the 
addition of a dopamine uptake inhibitor, nomifensine. Under these conditions nomifensine 
increased the in vivo recovery of dopamine. Theoretical models have suggested the increase in 
vivo probe recovery observed with DAT inhibition results from the zone of disrupted tissue 
surrounding the probe wherein dopamine uptake exceeds release.22, 23, 58-60 The next two chapters 
discuss benefits of utilizing DEX retrodialysis to mitigate the probe penetration injury and 
enhance long-term microdialysis sampling of dopamine measured with FSCV.  
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1.5 SPREADING DEPOLARIZATION AND CLINCAL MICRODIALYSIS  
Microdialysis, initially developed for use in the animal brain, has since been adapted for 
neurochemical monitoring in clinical settings.5 One application of clinical microdialysis is 
monitoring brain injured patients in the intensive care unit (ICU) to identify chemical markers of 
secondary brain injuries. Traumatic brain injury (TBI) is a significant public health problem, 
often referred to as a silent epidemic due to the numerous complications associated with a 
TBI.61, 62 In the United States 1.7 million TBI cases result in 53,000 deaths and 275,000 
hospitalizations a year.63 The primary injury can expand into the surrounding at risk tissue, 
termed the penumbra, resulting in secondary brain injuries.64-67 Forms of secondary injury 
include rises in intracranial pressure, ischemia, hypoxia, seizures, and spreading depolarization 
(SD).  
In the hours and days following the primary injury episodes of SD occur spontaneously in 
approximately 60% of TBI patients.68-71 The occurrence and frequency of SD is a major source 
of the heterogeneity of this complex disease and is proving to be a major factor in predicting 
patient outcome. Incidences of SD are significantly correlated with poor patient outcomes, 
including death, vegetative state, and severe disability.64-66 
Spreading depolarization is characterized by a wave of near-complete depolarization of 
neurons and glia resulting in a temporary disruption of the ion homeostasis and silencing of 
electrical activity.65 Excess K+ released into the extracellular space during SD can diffuses to and 
depolarizes neighboring cells, thus creating a wave that propagates across the cortex at a rate of 
2-5 mm/minute. Following the SD there is a large energy demand essential for the repolarization 
of cell membranes. The brain tissue depends on the vasculature to deliver glucose and oxygen to 
meet these energy demands, however swelling and restricted blood flow, commonly observed 
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after a TBI, can hinder this process. Clusters of SD impose particularly severe energy demands 
on the injured brain and can result in long-lasting declines in basal glucose.16, 67-73  
The importance of SD monitoring during neurointensive care has been widely recognized 
and numerous animal studies have been dedicated to improving SD monitoring.64-66, 74 Methods 
for SD monitoring include electrocortiography (ECoG), blood flow analysis, and microdialysis. 
The Boutelle lab has developed a rapid sampling microdialysis (rsMD) system that monitors SD-
associated changes in glucose and lactate at the patient’s bedside.75 Combining the rsMD system 
with an online K+ ion-selective electrode (ISE) and ECoG provides a multimodal analysis system 
that can detect episodes of SD in the days following the patient’s primary injury.76-78 The fourth 
chapter describes the DEX enhanced sampling of SD-induced changes in K+ and glucose 10 days 
after inserting a microdialysis probe into the rat cortex.  
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2.0  MICRODIALYSIS IN THE RAT STRIATUM: EFFECTS OF 24 HOUR 
DEXAMETHASONE RETRODIALYSIS ON EVOKED DOPAMINE RELEASE AND 
PENETRATION INJURY  
The contents of this chapter have been adapted with permission from: Nesbitt, K.M., 
Varner, E.L., Jaquin-Gerstl, A., Michael, A.C., ACS Chem. Neurosci. 2015, 6, 163-173. 
Copyright 2014 American Chemical Society. 
 
Dr. Andrea Jaquins-Gerstl contributed the immunohistochemistry and fluorescence 
microscopy work presented in this chapter.  
2.1 INTRODUCTION 
Intracranial microdialysis is ideally suited for real-time chemical monitoring in the 
brain,16, 41, 79-90 the benefits of which are well-known and have been reviewed often.1-4, 91-95 The 
microdialysis membrane keeps the dialysate samples free of large molecules and other debris, 
thus the dialysate is compatible with numerous analytical techniques. Many studies have been 
dedicated to refining both the microdialysis probes themselves and the analytical methods used 
to analyze the dialysate samples.8, 12, 96-104 Here, we wish to contribute to this ongoing refinement 
effort by focusing attention on what happens when the probes are implanted into brain tissue. 
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In practice, two major and intertwined challenges remain to be solved. First, when 
microdialysis probes are inserted into brain tissue, a wound response is triggered.22, 25-31, 33, 105-109 
Consequently, the dialysate samples are derived from the injured, abnormal tissue near the probe 
track. The wound response involves a cascade of events, some of which begin right away and 
some of which develop over the course of several days. Microglia respond within minutes to 
focal brain injury, whereas astrocytes respond later forming a barrier around the microdialysis 
probe after 5 days.31, 42, 110 Probe implantation also causes ischemia, disruption of the blood-brain 
barrier, and neuronal loss.30-31, 33, 105  
Second, minimal quantitative information is available as to how the concentration of 
substances in the outflow of microdialysis probes are related to the concentration of substances 
in the injured tissue next to the probes, or how concentrations in the injured tissue next to the 
probes are related to concentrations in the non-injured surroundings. These concentration 
relationships have been the subject of theoretical considerations but relatively few direct 
measurements.59, 111, 112 Neurochemical instability over the postimplantation intervals has been a 
long-standing issue in the field of microdialysis.24, 36-38, 57, 113-115 Even so, the dialysate content of 
neurotransmitters exhibits sensitivity to tetrodotoxin,41 responds predictably to various drugs,100, 
116-118 and correlates with behaviors.1, 4, 15, 80, 83 These observations show that microdialysis 
provides valid and useful indices of neurochemical activity.  
A prior study from our laboratory demonstrated the beneficial effects of the retrodialysis 
of dexamethasone (DEX), a potent anti-inflammatory steroid, on the tissue penetration injury and 
dopamine (DA) concentrations in the tissue surrounding the probe 4 h after probe insertion.33 
DEX diminished the loss in amplitude of evoked DA responses measured directly next to the 
probe with fast-scan cyclic voltammetry (FSCV). Histochemical data provided clear evidence 
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that the anti-inflammatory actions of DEX prevented ischemia, astrocyte and microglia 
activation, and the loss of neurons near the probe track.31, 33  
Herein, we implanted microdialysis probes in the rat striatum for 4 and 24 h, both with 
and without DEX in the perfusion fluid, and then measured evoked DA release at the outlet of 
the probes with FSCV. Responses at the probe outlet were below the detection limits of FSCV 
unless animals were treated with the DA uptake inhibitor, nomifensine, which increases the 
microdialysis recovery of evoked dopamine transients.23, 116, 119 When probes were perfused 
without DEX, post-nomifensine responses at the probe outlet exhibited a significant decline in 
amplitude between 4 and 24 h postimplantation. However, DEX abolished this instability, both 
in animals treated first with nomifensine and then with raclopride. Thus, we report here for the 
first time that DEX stabilizes, but does not alter, evoked dopamine responses at the outlet of 
microdialysis probes. DEX had no significant effect on two key tissue markers for dopamine 
terminals, tyrosine hydroxylase (TH) and the dopamine transporter (DAT). We therefore 
attribute DEX’s effects on evoked dopamine responses at the outlet of microdialysis probes to its 
anti-inflammatory actions, as opposed to any direct actions on dopamine terminals. Finally, we 
report for the first time that the penetration of DEX into the tissue near the probe is extremely 
limited. Fluorescein-labeled DEX was found no further than 80 μm from its delivery probe. We 
therefore conclude that DEX’s anti-inflammatory actions are tightly confined to the immediate, 
local vicinity of the probe. 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Voltammetry Next to the Probe 
Electrical stimulation of DA axons in the medial forebrain bundle (MFB) evokes DA 
release in the ipsilateral striatum, which is easily measurable by FSCV.120-123 Previous studies 
have shown when microelectrodes are implanted into the tissue next to the microdialysis probe 
there is a decreasing gradient of evoked DA release the closer the microelectrode is placed to the 
microdialysis probe.24, 40 When microelectrodes are implanted next to the microdialysis probe 
(70-100 μm from the probe) evoked DA responses are abolished by 4 h after probe 
implantation.33 Previously, the retrodialysis of DEX diminished, but did not eliminate, the loss in 
amplitude of the evoked responses next to the microdialysis probe.33 Additional data obtained 
next to the microdialysis probe is provided in the original version of this research article.  
2.2.2 Voltammetry at the Probe Outlet 
FSCV was performed at the outlet of microdialysis probes to quantify evoked responses 
in the dialysate stream (Figure 2-1). The stimulus parameters were 45 Hz, 300 μA, 25 s. The 
evoked responses are reported in Figure 2-2, in which the time axes have been adjusted to 
account for the time needed for the dialysate to flow from the probe to the end of the outlet line: 
the transit time was confirmed by calibration and agreed with calculated values. The vertical 
axes in Figure 2-2 were obtained by postcalibration of the detection electrode in a flow cell 
apparatus without correction for probe recovery, so the vertical axes report dialysate, not in vivo, 
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DA concentrations. The DA responses in Figure 2-2 exhibit some baseline drift: this is due to the 
electrode pretreatment strategy used to optimize the sensitivity of the electrodes (see Methods). 
 
 
Figure 2-1. 
Diagram for voltammetry at the microdialysis probe outlet. 
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Figure 2-2.  
Effect of aCSF and DEX on the average (±SEM) evoked DA release measured at the probe outlet pre-nomifensine 
(red), after nomifensine (green), and after both nomifensine and raclopride (purple). Evoked release was measured 
(a, b) 4 h and (c, d) 24 h after probe implantation (n = 6 per group). A negative dopamine concentration means that 
the current dropped below the baseline current response as a result of the baseline drift from the electrochemical 
pretreatment of the carbon fiber (see Methods). 
 
Evoked DA release was nondetectable at the outlet of probes perfused with aCSF or DEX 
for 4 or 24 h (Figure 2-2, red lines). This is consistent with our prior experience that evoked DA 
responses at the probe outlet are below the detection limits of FSCV unless the DA uptake 
mechanism is inhibited.23, 40, 58 This observation is also consistent with the results of our 
measurements next to the microdialysis probe.33 In the case of perfusion with aCSF, evoked 
responses are below FSCV detection limits next to the probe, which explains why no response 
was detected at the probe outlet. DEX significantly increased the response amplitude next to the 
probe but evidently, not sufficiently enough to produce a detectable response at the probe outlet. 
Evoked DA release was detected at the probe outlet following administration of the 
dopamine uptake inhibitor, nomifensine (20 mg/kg i.p., Figure 2-2, green lines), consistent with 
the ability of nomifensine to increase evoked responses next to the probe. In the case of probes 
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perfused with aCSF, the post-nomifensine response was not stable: the response amplitude 
declined significantly between 4 and 24 h after implantation (Figure 2-3, statistics reported in 
figure legend). No such instability was observed next to the probe, which suggests that responses 
closer to the probe are affected more, as we have previously suggested.24 DEX eliminated this 
instability: in the presence of DEX, there was no significant difference in the responses at the 
probe outlet at 4 and 24 h postimplantation (Figure 2-3). Hence, we report here for the first time 
on DEX’s ability to stabilize evoked responses at the probe outlet over the 4–24 h 
postimplantation interval. 
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Figure 2-3.  
Average maximum evoked DA concentration (±SEM) observed at the outlet of microdialysis probes after 
nomifensine comparing 4 h (pink, n = 6) and 24 h (orange, n = 6) after probe implantation. In a two-way ANOVA 
time (4, 24 h), F(1,20) = 9.86, p < 0.01, and treatment (aCSF, DEX), F(1,20) = 6.37, p < 0.05, were significant 
effects on the DA concentration post-nomifensine. There was no significant interaction F(1,20) = 2.82, p > 0.05. In a 
post hoc pairwise comparisons with Bonferroni corrections, there is a significant difference between aCSF at 4 and 
24 h and between aCSF and DEX at 24 h. *p < 0.01 and **p < 0.005. 
 
The statistical analysis also shows there were no significant differences between the 
response amplitudes measured at the outlet of probes perfused with DEX and those perfused for 
4 h with aCSF (Figure 2-3). Thus, DEX stabilized, but does appear to have altered, the responses 
at the probe outlet. 
Following the administration of nomifensine, rats received a single dose of the D2 DA 
receptor antagonist, raclopride (2 mg/kg i.p.), and a final evoked response was measured at the 
probe outlet (Figure 2-2, purple lines). As expected,57, 121, 124, 125 the autoreceptor antagonist 
caused a further increase in the response amplitudes, as summarized in Figure 2-4. Statistical 
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analysis of Figure 2-4 was by a mixed-model three-way ANOVA of time (4 h, 24 h), perfusion 
medium (aCSF, DEX), and drug (nomifensine, raclopride, with repeated measure) as the main 
factors (details in the figure legend). The responses at the outlet of probes perfused with aCSF 
significantly diminished between 4 and 24 h postimplantation. There were no significant 
differences between the responses observed in the 4 h aCSF, 4 h DEX, and 24 h DEX cases: this 
shows that DEX stabilized but did not alter these responses. Raclopride significantly increased 
the evoked responses in the 4 h aCSF, 4 h DEX, and 24 h DEX cases but not in the 24 h aCSF 
case. 
 
 
Figure 2-4.  
Average maximum evoked DA concentration (±SEM) collected by the probe. A three-way ANOVA with repeated 
measures was completed comparing the effects of time (4, 24 h), treatment (aCSF, DEX), and drug (nomifensine, 
raclopride). As seen in the nomifensine data, time F(1,20) = 10.4, p < 0.005; treatment F(1,20) = 7.52, p < 0.05; and 
now the interaction between treatment and time F(1,20) = 8.47, p < 0.01 are significant. The effect of drug (between 
nomifensine and raclopride) was significant F(1,20) = 74.7, p < 0.00000005, and the interaction between time and 
treatment and drug was also significant F(1,20) = 14.5, p < 0.05. A post hoc pairwise comparison with Bonferroni 
corrections shows a significant increase from nomifensine to raclopride in 3 of the 4 experiments. *p < 0.005 and 
**p < 0.000005. 
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Thus, as judged on the basis of evoked responses measured at the outlet of microdialysis 
probes, DEX eliminated the instability in DA neurochemistry between 4 and 24 h post 
implantation in animals treated first with nomifensine and then with raclopride. Perfusion with 
aCSF for 24 h caused a loss in the significance of the effects of both nomifensine and raclopride 
combination. The loss in amplitude reported here is consistent with several prior reports of 
instability of DA following probe implantation.36-38, 40 
During the 24 h experiments a second carbon fiber microelectrode was inserted into the 
tissue to record in vivo evoked responses. The electrode was positioned 1.5 mm from the probe 
to ensure the electrode was outside of the zone of tissue disrupted during the probe insertion.24, 40 
While there was a significant difference in the outlet responses with and without DEX (Figures 
2-3 and 2-4), there was no significant difference observed at the electrode 1.5 mm from the probe 
(Figure 2-5). This confirms the instability at the probe outlet is due to the disruption of the tissue 
in the immediate vicinity of the probe. In the 4 h experiment the in vivo electrode was removed 
prior to probe insertion, as described in the methods section.  
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Figure 2-5. 
Average (±SEM) in vivo evoked DA concentration recorded 24 h after probe insertion. The carbon fiber 
microelectrode was positioned 1.5 mm from the probe. A two-way ANOVA with repeated measures was completed 
with treatment (aCSF, DEX) and drug (pre-nomifensine, nomifensine, and nomifensine/raclopride) as the factors. 
Drug was a significant factor, F(2,20) = 24.579, p > 0.00005, but treatment and the interaction were not significant.   
2.2.3 Immunohistochemistry of the Probe Track 
We performed histochemical analysis of striatal tissues using antibodies for two widely 
accepted markers of DA terminals, tyrosine hydroxylase (TH) and the DAT.126-128 The tissue 
exhibited nonlabeled areas corresponding to myelinated axon bundles. Additionally, the probe 
tracks are clearly visible in the center of the images shown in Figure 2-6. Some diffuse labeling 
around probes perfused with aCSF is evident in the TH image (Figure 2-6, middle column): we 
have observed such binding before and consider it an edge effect.33, 129 Overall, TH and DAT 
labeling was clearly evident near the tracks of probes perfused both with and without DEX 
(quantification is discussed, below). 
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Figure 2-6. 
Separate columns illustrate representative fluorescent images of striatal tissue with no probe, or after retrodialysis of 
aCSF, or DEX for 24 h. Separate rows provide tissue labeled with TH (top) or DAT (bottom). Scale bars are 
200 μm. 
 
The intense TH labeling near probe tracks perfused with aCSF for 24 h stands in clear 
contrast to the absence of TH labeling that we observed 4 h after implantation.33 The exact 
mechanism whereby this interesting rebound of TH labeling occurs is not yet known: 
possibilities, to be explored further in future studies, might include the synthesis of new TH 
protein by surviving DA terminals and/or the sprouting of new DA terminals.130, 131 
The TH and DAT images were converted to 2D intensity scatter plots, from which we 
determined Pearson’s correlation coefficient (PCC) and Manders’ overlay coefficient (MOC) 
(see the methods for explanations of these coefficients).132 The correlation coefficients in images 
with and without probe tracks are indistinguishable for probes perfused with DEX (Figure 2-7). 
The correlation coefficients are only slightly reduced with aCSF compared to DEX, most likely 
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due to the nonspecific edge effect.133 Overall, the probes with DEX had no significant effect on 
the correlation of TH and DAT labeling in the nearby tissue (see Figure 2-7 legend). Regions of 
interest in the TH and DAT labeled images were defined to eliminate the probe track. There were 
no significant differences in the quantitative TH and DAT labeling in nonimplanted control 
tissue and the regions of interest around the tracks of probes perfused for 24 h with either aCSF 
or DEX (Figure 2-7b). 
Figure 2-7. 
(a) Correlation coefficients between TH and DAT pixels among the three groups (no probe, aCSF and DEX, n = 3
rats (total of 6 images per group)) for both Mander’s overlay (black) and Pearson’s correlation (green). A two-way
ANOVA comparing the treatment (no probe, aCSF, and DEX) and analysis (Pearson’s correlation and Mander’s
overlay) showed that there were significant differences in treatment F(2,28) = 14.2, p < 0.0001, analysis F(1,28) =
29.7, p < 0.00001, and the interaction treatment and analysis F(2,28) = 3.87, p < 0.05. A post hoc Tukey test further
showed aCSF correlation coefficients were significantly reduced compared to no probe (p < 0.0005) and DEX (p <
0.0001). A post hoc pairwise comparisons with Bonferroni corrections showed that Mander’s overlay and Pearson’s
correlation differ from each other with no probes (p < 0.05) and aCSF (p < 0.00005). (b) Average fluorescent
intensity for TH (red) and DAT (blue) for no probe, aCSF, and DEX (n = 3 rats (total of 6 images per group)).
Fluorescent intensity ranges from 0 to 255 with 255 being the highest value. In a two-way ANOVA comparing
treatment (no probe, aCSF, and DEX, F(2,30) = 0.97, p > 0.05) and stain (TH and DAT, F(2,30) = 0.74, p > 0.05),
there were no significant differences in average fluorescent intensity.
Overall, probe implantation had no significant effect on TH and DAT, two key markers 
for DA terminals. This supports our conclusion that DEX’s effects on evoked responses are 
attributable to its previously documented anti-inflammatory actions,31, 33 as opposed to direct 
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actions on DA terminals. Our prior studies show that DEX profoundly decreases ischemia, glial 
activation, and neuron loss in the tissues near microdialysis probes.31, 33 It appears that these 
actions are responsible for the effects of DEX on evoked DA responses next to and at the outlet 
of microdialysis probes over the 4−24 h post-implantation interval. 
2.2.4 Evaluating the Tissue Penetration of Dexamethasone 
We used fluorescein-labeled DEX (DEX-FL) to assess how far DEX penetrates into the 
tissue near microdialysis probes. After 4 h of retrodialysis, DEX-FL penetrated only to 78.6 ± 
46.1 μm from the probe track (Figure 2-8). This result, however, might be affected by the 
detection limit of the fluorescence measurement and possibly by loss of soluble DEX-FL during 
tissue processing. We therefore conclude that DEX does not penetrate deeply into brain tissue 
and that its actions are confined to within close proximity to the delivery probe. 
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Figure 2-8. 
Images of the microdialysis probe track, from three different rats, after 4 h perfusion of DEX-FL. DEX-FL is 
delivered locally only to the tissue directly surrounding the probe. The white lines mark the distance of DEX-FL 
from the microdialysis probe track.  
2.3 CONCLUSIONS 
Our findings reiterate that tissue damage occurs when a microdialysis probe is implanted 
into brain tissue.25, 26, 28, 30, 31, 33, 105 The disruption of the tissue surrounding the microdialysis 
probe results in neurochemical and histological disruptions over the 4−24 h postimplant interval, 
a typical time frame for microdialysis studies.3, 8, 41, 97 Here, based on the evoked DA responses 
measured at the outlet of the probe, we have documented for the first time that DEX eliminates 
such instability over the 4-24 h time interval following probe insertion. DEX stabilizes, but does 
not alter, evoked dopamine responses at the outlet of microdialysis probes following the 
sequential administration of nomifensine and raclopride. The actions of DEX reported here 
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appear to derive from its anti-inflammatory actions,31, 33 rather than any direct neurochemical 
impact on the DA terminals. Additionally, the actions of DEX are confined to the tissue directly 
surrounding the microdialysis probe. 
2.4 METHODS 
The methods used during this study have been described previously.23, 24, 30, 31, 33, 57, 105 
2.4.1 Reagents and Solutions 
All solutions were prepared with ultrapure water (Nanopure, Barnstead, Dubuque, IA). 
All reagents were used as received from their suppliers. Artificial cerebrospinal fluid (aCSF: 142 
mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 mM MgCl2, 2.0 mM NaH2PO4, pH 7.4) was the 
perfusion fluid for microdialysis. DEX sodium phosphate (DEX, APP Pharmaceuticals LLC 
Schaumburg, IL) was diluted to 10 μM in aCSF. This dose was used as we have previously 
observed a dramatic reduction in tissue disruption at 10 μM DEX for 24 h.31 DEX fluorescein 
(DEX-FL, Life Technologies Grand Island, NY) was diluted to 10 μM in aCSF. Nomifensine 
maleate and S(−)-raclopride (+)-tartrate salts (SigmaAldrich, St. Louis, MO) were dissolved in 
phosphate-buffered saline (PBS: 155 mM NaCl, 100 mM NaH2PO4, pH 7.4) and administered at 
20 mg/kg (i.p.) and 2 mg/kg (i.p.), respectively. Isopropyl alcohol (Sigma-Aldrich, St. Louis, 
MO) and decolorizing carbon (Fisher, Pittsburgh, PA) were used to pretreat carbon fiber 
electrodes for DA voltammetry. DA (Sigma-Aldrich, St. Louis, MO) standards were prepared in 
N2-purged aCSF. 
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2.4.2 Fast Scan Cyclic Voltammetry and Electrochemical Pretreatment  
Carbon fiber electrodes were constructed by threading a single carbon fiber (7 µm 
diameter, T650, Cytec Carbon Fibers LLC., Piedmont, SC) through borosilicate capillaries 
(0.58 mm I.D., 1.0 mm O.D., Sutter Instruments, Novato, CA). The capillaries were pulled to 
fine tips around the carbon fiber with a vertical puller (Narishing Tokyo, Japan). Carbon fibers 
were glued in place with a low viscosity epoxy (Spurr Epoxy, Polysciences Inc., Warrington, 
PA) and cured overnight at 70 ºC. The exposed carbon fiber was cut to a length of 400 µm for in 
vivo studies or 800 µm for detection at the outlet of microdialysis probes. Capillaries were 
backfilled with mercury and a nichrome wire (Goodfellow, Oakdale, PA) was placed into the 
mercury to make an electrical connection.  
Fast scan cyclic voltammetry (FSCV) was executed using a computer controlled EI-400 
potentiostat (Ensman Instruments, Bloomington, IN) with CV Tarheels version 4.3 software 
(Michael Heien, University of Arizona, Tucson AZ). A triangular waveform was applied as a 
linear sweep (vs Ag/AgCl) from 0 V to 1 V, then to -0.5 V, and then back to the resting potential 
of 0 V at a scan rate of 400 V/s. Scans were performed at a frequency of 2.5 Hz unless otherwise 
noted. Background subtracted voltammograms were used to quantify DA on the initial potential 
sweep between 0.6 V and 0.8 V. The DA current was converted to concentrations by post-
calibrations with freshly prepared standard solutions of DA (Sigma Aldrich, St. Louis, MO) 
dissolved in nitrogen purged aCSF. 
In addition to the isopropyl alcohol pretreatment, 800 μm electrodes were 
electrochemically pretreated (0-2V vs. Ag/AgCl at 200 V/s for 3 s) exactly 10 min before each 
collection. The electrode was pulled out of the outlet before each pretreatment and re-lowered 
immediately after it was complete. To reduce resistance, the electrode was positioned so that 
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majority of the carbon fiber was inside the outlet. The pretreatment causes a drift in the signal, 
which is noticeable when detecting low concentrations close to the detection limit (~20-30 
nM).23 For this reason the pretreatment was completed exactly 10 min before each collection at 
the outlet, followed by a 60 Hz waveform scan for 60 s to help stabilize the drift. The 
pretreatment had no impact on the brain tissue because the in vivo electrode was outside of the 
path of the electrochemical cell. 
2.4.3 Microdialysis Probes 
Concentric microdialysis probes (300 μm diameter, 4 mm length) were constructed with 
hollow fiber membranes (13 kDa MWCO, Specta/Por RC, Spectrum Laboratories Inc., Ranco 
Dominguez, CA). The inlet tubing (PE, Becton Dickinson, Franklin Lakes, NJ) was connected to 
a 1 mL gastight syringe driven by a microliter syringe pump (Harvard Apparatus, Holliston, MA) 
at a rate of 0.610 μL/min. The outlet was a fused silica capillary (75 μM I.D., 150 μM O.D., 10 
cm long; Polymicro Technologies, Phoenix, AZ). Probes were perfused with either aCSF or 
aCSF containing 10 μM DEX. 
2.4.4 Surgical Procedures 
All procedures involving animals were approved by the University of Pittsburgh’s 
Animal Care and Use Committee. Male Sprague−Dawley rats (250−350 g; Hilltop, Scottsdale, 
PA) underwent sterile stereotaxic surgery under isoflurane anesthesia. The probes were lowered 
into the brain at 5 μm/s with an automated micropositioner (model 2660, David Kopf 
Instruments, Tujunga, CA). For all voltammetry experiments, the reference and stimulating 
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electrodes were placed in the same positions in the brain. Reference electrodes were connected to 
the brain via a salt bridge. Bipolar stimulating electrodes were lowered into the medial forebrain 
bundle (MFB) until maximum DA release was observed (4.3 mm posterior and 1.2 mm lateral 
from bregma). Electrically evoked DA release was recorded by FSCV during stimulation of the 
MFB (stimulus waveform: biphasic, square, constant current pulses 300 μA pulse height, 4 ms 
pulse width). The waveform was delivered for 25 s at 45 Hz.  
2.4.5 Voltammetry at the Probe Outlet 
Voltammetry at the probe outlet was performed in a custom-made Plexiglas detection 
chamber (Figure 2-1). A carbon fiber electrode (800 μm long) was inserted into the end of the 
capillary outlet line with a miniature micromanipulator (Fine Science Tools, Foster City, CA). 
As described previously,23 the electrodes were electrochemically pretreated 10 min before each 
stimulus or calibration procedure. 
Voltammetry at the outlet was performed in four groups of rats, 4 or 24 h (n = 6 per 
group) after probe implantation, with perfusion of aCSF or DEX. Animals in the 4 h group 
remained under isoflurane anesthesia throughout the experiment. 
For the 4 h study, anesthetized rats were placed in a stereotaxic frame and adjusted to flat 
skull. Three holes were drilled in the skull and the dura was carefully removed to expose the 
brain. A carbon fiber electrode was inserted into the striatum (0.7 mm anterior to bregma, 2.5 
mm lateral from bregma, and 5.0 mm below dura), and a stimulating electrode was lowered to 
the MFB. Three evoked DA responses were recorded in 20 min intervals to establish a stable, 
pre-probe response. The electrode was removed and a microdialysis probe was inserted using a 
micropositioner (5 μm/sec) in the same location except 7.0 mm below dura. After 2 h, evoked 
 27 
DA release was monitored in the outlet. Following three initial 25s stimulations, nomifensine 
and raclopride were sequentially administered and evoked DA monitored 25 minutes later. 
For the 24 h study, a microdialysis probe was lowered into the brain of an anesthetized 
rat (1.6 mm anterior to bregma, 2.5 mm lateral from bregma, and 7.0 mm below the dura) at 5 
μm/s with an automated micropositioner and secured to the skull with bone screws and acrylic 
cement. Following surgery, the rats were placed in a Raturn microdialysis bowl (MD-1404, 
BASI, West Lafayette, IN) and the probes were perfused with aCSF or DEX for 24 h.  After a 
24 h recovery the rats were re-anesthetized and returned to the stereotactic frame. A 400 μm 
carbon fiber electrode was inserted into the striatum (0.45 mm anterior to bregma, 3.5 mm lateral 
from bregma, and 5.0 mm below dura), the stimulating electrode was positioned at the MFB, and 
detection at the outlet and in vivo were completed the in same order as the post-probe procedure 
in the 4 h study. 
2.4.6 Tissue Immunohistochemistry 
After the in vivo measurements, the rats were deeply anesthetized and the brain tissues 
were collected for immunohistochemical analysis.30 Thin horizontal sections (35 μm) were cut in 
a cryostat at −21 to −22 °C and labeled together with antibody for tyrosine hydroxylase (TH; 
1:1000, Millipore, Temecula, CA) and the DA transporter (DAT; 1:400, Synaptic Systems, 
Göttingen, Germany). The secondary antibody was goat anti-rabbit IgG-Cy3 or IgG-Cy5 
(Invitrogen, Eugene, OR). In another group of rats, probes perfused with DEX-FL were 
implanted for 4 h. Fluorescence and optical differential interference contrast (DIC) images were 
acquired with an Olympus BX61 microscope (Olympus; Melville, NY) equipped with a 20× 
objective. Nonimplanted tissue (from the hemisphere opposite the microdialysis probe) was used 
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as control tissue. Quantitative image analysis was performed with NIS-Elements Advanced 
Research version 4.00 software (Nikon Instruments Inc., Melville, NY). Images were batched 
processed using the “smart threshold function” in the software to automatically set threshold 
limits and disregard background pixels.  
2.4.7 Fluorescent Dexamethasone Procedure 
Microdialysis probes were implanted for 4 hr during which dexamethasone fluorescein 
(10 µM) was perfused through the probe (n=3 rats). Horizontal sections (30 µm) were taken 
along the probe tract (130 slices per rat). Three random sections from each rat were imaged, 
thresholded and masked. Using NIS Element Advanced Research software random line 
measurements were perform in the area defined as a positive fluorescent signal. Nine different 
line measurements were made from each image for a total of 81 measurements (see Figure 2-8). 
2.4.8 Defining TH and DAT Colocalization  
Fluorescence microscopy was used to examine the colocalization of tissue labeled for 
tyrosine hydroxylase (TH) and dopamine transporters (DAT). For each probe track, images of 
both TH and DAT were collect using sequential mode, allowing for images to be merged and a 
composite image created. Since it is difficult to visualize the degree of colocalization from a pair 
of images, an important alternative is to display the intensities of the pairs of homologous pixels 
in a 2D scatterplot. The two antibodies were analyzed for the degree of colocalization by 
measuring the equivalent pixel position in each of the acquired images by generating a 2D-
scatterplot (Fig. 2-7a). Each axis covers the range of intensities of the fluorophores, in our case 
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Cy3 and CY5 (respectively, TH and DAT). The scatterplot shows the frequency of occurrence 
between the pair of intensities which reveals any correlation between the fluorophores. The 
relationship between the intensities in the two images is calculated by linear regression. The 
slope of this linear approximation provides the rate of association of the two fluorophores.134 
Following the generation of the scatterplot it is possible to quantitatively evaluate colocalization 
between the fluorophores (TH and DAT). Values calculated for the scatterplot using NIS 
Element Advanced Research software include Pearson’s Correlation Coefficient (PCC), and 
Manders’ Overlap Coefficient (MOC). Pearson’s Correlation and Manders’ Overlap are 
mathematically similar differing in the use of either absolute intensities (Manders’) or the 
deviation from the mean (Pearson’s).134, 135 Pearson’s Correlation is well defined and is an 
accepted means for describing overlap between image pairs. It’s computed values are between -1 
to 1 with -1 being no overlap, 1 being perfect overlap and 0 representing random distributions 
between images. Only the similarities of shapes between images are account for not their 
intensities. PCC is defined as:136, 137 
 
where Ri= intensity in red channel, 𝑅𝑅 ̅= average intensity in red channel, 𝐺𝐺𝑖𝑖= intensity in green 
channel and 𝐺𝐺 ̅= average intensity in green channel. 
MOC is also used to describe overlap however this method does not perform any pixel 
averaging functions like that of PCC therefore values range from 0 to 1. This method is also not 
sensitive to intensity variations between images. MOC is defined as:136 
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2.4.9 Statistics  
IBM Statistical Package for the Social Sciences (SPSS) 22 software was used for all statistical 
analysis. 
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3.0  ENHANCED INTRACRANIAL MICRODIALYSIS BY REDUCTION OF 
TRAUMATIC PENETRATION INJURY AT THE PROBE TRACK 
Reprinted with permission from Varner, E.L., Jaquins-Gerstl, A., Michael, A.C., ACS 
Chem. Neurosci. 2016, 7, 728-736. Copyright 2016 American Chemical Society. 
 
Dr. Andrea Jaquins-Gerstl contributed the immunohistochemistry and fluorescence 
microscopy work presented in this chapter.  
3.1 INTRODUCTION 
Microdialysis is a powerful and popular approach for intracranial chemical monitoring.1-4 
There are several reasons for this. The probes sample a broad array of interesting substances, 
limited mainly by the molecular weight cutoff of the dialysis membrane. Because the dialysate 
samples are free of macromolecules, blood, and cellular debris, they are suitable for near real-
time analysis by online methods without further sample preparation. Brain dialysate is 
compatible with a variety of high-performance analytical methods, including HPLC, capillary 
electrophoresis, and mass spectrometry. Recent enhancements of such methods have produced 
substantial gains in temporal resolution.8, 9, 11 The power and utility of microdialysis has spawned 
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a vast literature on intracranial monitoring in awake, freely moving animals and in human 
patients with brain injury.1-4, 8, 9, 11, 16 
Nevertheless, implanting a microdialysis probe causes a traumatic penetration injury in 
the brain tissue that triggers ischemia, opens the blood–brain barrier, activates astrocytes and 
microglia, damages neurons, axons and terminals, and leads to scar formation at the probe 
track.25-28, 31, 33, 34 This scenario is not unique to microdialysis, as the tissue response also 
confronts brain–machine interfaces.42, 47 The penetration injury significantly perturbs the 
neurochemistry of the tissue from which the dialysate samples are obtained24, 33, 34, 57 and 
contributes to the loss in probe patency over time following implantation.36-40 Thus, our objective 
is to reduce, if not eventually eliminate, the penetration injury and its deleterious effects on 
neurochemical monitoring. 
Herein, we show that combining a 5-day postimplantation wait period with the 
continuous retrodialysis of a low-micromolar concentration of dexamethasone vastly reduces 
both the voltammetric and histological signs of the penetration injury. Dexamethasone (DEX) is 
a glucocorticoid anti-inflammatory agent. We have previously documented that continuous DEX 
retrodialysis (DEXretro) diminishes the effects of the penetration injury at 4 and 24 h after probe 
implantation.33, 34 However, we now show that at 5-days after probe implantation DEXretro 
reinstates normal evoked dopamine (DA) release activity in the tissue adjacent to the probe, 
facilitates robust detection of evoked DA release at the probe outlet (i.e., without the aid of a DA 
uptake inhibitor), establishes quantitative agreement between evoked DA measured 
simultaneously at the probe outlet and in the tissue next to the probe, reinstates normal 
immunoreactivity for tyrosine hydroxylase (TH) and the dopamine transporter (DAT) near the 
probe, and prevents glial scarring at the probe track. Our findings support the conclusion that the 
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beneficial effects of DEX in this application may be attributed to its actions as an anti-
inflammatory agent. 
3.2 RESULTS AND DISCUSSION 
3.2.1 Experimental Design 
Microdialysis probes were implanted unilaterally into the striatum of rats and perfused 
continuously for 5 days with or without DEXretro. As before,31 we perfused the probes with 10 
μM DEX for the first 24 h after probe implantation and then switched to 2 μM DEX thereafter. 
Five days after probe implantation, the rats were reanesthetized and returned to a stereotaxic 
frame, where they remained for the duration of the measurements reported below. A stimulating 
electrode was placed in the medial forebrain bundle ipsilateral to the microdialysis probe, and a 
carbon fiber electrode was placed in the striatum at a location 1.0 or 1.5 mm from the 
microdialysis probe, as specified below. The outlet capillary of the microdialysis probe was 
threaded into a detection chamber and interfaced to a second carbon fiber microelectrode (Figure 
3-1). This setup permits evoked DA responses to be recorded by fast scan cyclic voltammetry 
(FSCV) simultaneously at the probe outlet and in the tissue adjacent to the probe. The 
stimulations were applied for 25 s at 45 Hz unless noted otherwise. The 25-s stimulus duration 
was selected, based on prior work, to match the response time of the microdialysis probes (see 
Figure 6 of ref 23). 
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Figure 3-1.  
Five days after implanting a microdialysis probe into the striatum, a carbon fiber electrode was placed 1.5 mm from 
the probe. The outlet of the microdialysis probe was threaded into a detection chamber and interfaced to a second 
carbon fiber electrode. This arrangement allows simultaneous recordings of evoked DA release at the probe outlet 
and in the tissue next to the probe. 
 
In the figures that follow, the time axes for responses recorded at the probe outlet are 
corrected to account for the time required for the dialysate to travel the length of the outlet 
capillary. DA concentrations recorded at the probe outlet have not been corrected for probe 
recovery. DEXretro had no significant effect on evoked DA responses recorded in the striatal 
tissue 1.5 mm from the microdialysis probes (Figure 3-S1). 
3.2.2 Evoked DA Responses Recorded at the Probe Outlet 
Figure 3-2 compares evoked DA responses recorded at the probe outlet 5-days after 
implantation with (red) or without (blue) continuous DEXretro. Without DEXretro, there was no 
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response (0 responses from 6 rats). With DEXretro, however, the response was both robust and 
reproducible (6 responses from 6 rats). 
 
 
Figure 3-2.  
Evoked DA responses (mean ± SEM, n = 6 per group) recorded at the outlet of microdialysis probes 5 days after 
implantation. Without DEXretro (blue) the stimulus evoked no response. With DEXretro (red), the stimulus evoked 
clear and reproducible responses. Inset: the average background-subtracted cyclic voltammogram obtained with 
DEXretro, showing the expected DA oxidation and reduction peaks. 
 
In our view, the evoked response recorded at the probe outlet after 5 days of DEXretro 
(Figure 3-2, red) represents a major step forward in our efforts to reduce, if not eventually 
eliminate, the effects of the penetration injury. During our prior studies at 4 and 24 h after probe 
implantation,23, 34, 40, 58 we have never observed a pre-nomifensine response by voltammetry at 
the probe outlet, either with or with DEXretro. The requirement for uptake inhibition stems from 
the tissue response, which abolishes evoked DA release in the tissue adjacent to the probe.24, 33, 34, 
57 Figure 3-2 is the first of several observations reported herein indicating a vast reduction in the 
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penetration injury by the combination of DEX retrodialysis and a sufficient postimplantation 
wait interval. 
To permit comparisons with evoked responses previously measured at 4 and 24 h after 
probe implantation,34 we recorded additional responses at the probe outlet after treating rats first 
with nomifensine (20 mg/kg i.p.), a DAT inhibitor, and then with raclopride (2 mg/kg i.p.), a 
dopamine D2 receptor antagonist (Figure 3-3 A,B). Figures 3-3 C and D summarize the 
maximum amplitude and the area under the curve (AUC) of the evoked responses. We 
performed the AUC analysis because the temporal profile of the outlet responses was somewhat 
altered after the 5-day wait interval (see Figures 3-S2 and 3-S3). The amplitude of the pre-
nomifensine response with DEXretro is significant (one-tailed t test). DEXretro significantly 
increased the post-nomifensine and post-nomifensine/raclopride amplitudes and AUCs 
(ANOVA; details are in the figure legend). 
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Figure 3-3.  
Evoked DA responses (mean ± SEM, n = 6 per group) measured at the outlet of microdialysis probes perfused with 
(A) aCSF or (B) DEX. DA was measured before nomifensine (red), after nomifensine (green), and then again after 
raclopride (purple). The amplitudes and AUCs are analyzed in C and D, respectively (ND = not detected). The 5 day 
DEXretro pre-nomifensine responses are significant when compared to zero (amplitude, t(5) = 3.27; AUC, t(5) = 3.40; 
one-tailed t test); § = p < 0.05. The amplitude and AUC results underwent 2-way ANOVA with treatment (aCSF, 
DEX) and drug (nomifensine and nomifensine/raclopride; repeated measurements) as factors. (C) Treatment 
(F(1,10) = 19.93, p < 0.005) and drug (F(1,10) = 26.96, p < 0.001) are significant factors: no significant interaction. 
(D) Treatment (F(1,10) = 18.25, p < 0.005) and drug (F(1,10) = 21.96, p < 0.001) are significant factors: no 
significant interaction. Asterisks report posthoc pairwise comparisons. ***p < 0.005. 
 
Without DEXretro, evoked responses at the outlet of probes implanted in animals treated 
with nomifensine and then with raclopride exhibited significant decreases in amplitude and AUC 
between 4 and 24 h after implantation and showed no tendency to rebound after 5 days (Figure 
3-4). However, with DEXretro there were no such declines (Figure 3-4). Instead, DEXretro 
stabilized the postdrug responses, which exhibited only minor differences among the 4 h, 24 h, 
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and 5 day time points. It is important to emphasize that different groups of animals were used for 
each time point and for each condition (aCSF and DEX). 
 
 
Figure 3-4.  
(A) Amplitude and (B) AUC (mean ± SEM, n = 6 per group) of evoked DA responses detected at the probe outlet 
(ND = not detected). The data at 4 h, 24 h, and 5 days are from separate groups of rats. The data at 4 and 24 h are 
from a prior study.34 The 5 day DEXretro pre-nomifensine responses are statistically significant compared to zero 
(amplitude, t(5) = 3.27; AUC, t(5) = 3.40; one-tailed t test, § = p < 0.05). Statistical analysis of the nomifensine and 
nomifensine/raclopride panels was by three-way ANOVA with time (4 h, 24 h, and 5 days), treatment (aCSF and 
DEX), and drug (nomifensine and nomifensine/raclopride; repeated measurements). Time (amp F(2,30) = 5.69, p < 
0.01, AUC F(2,30) = 4.66, p < 0.05), treatment (amp F(1,30) = 21.8, p < 0.001, AUC F(1,30) = 28.1, p < 0.001), and 
drug (amp F(1,30) = 100, p < 0.001, AUC F(1,30) = 57.2, p < 0.001) are significant factors. Interactions are 
significant. Asterisks indicate posthoc pairwise comparisons. *p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 
0.001. 
3.2.3 Comparison of Outlet and In Vivo Responses 
Figure 3-5 compares the amplitudes of responses recorded at the probe outlet after 5 days 
of continuous DEXretro (Figure 3-5A) to the amplitudes of in vivo responses recorded in the 
tissue adjacent to the probe (the probe–electrode separation was 1.5 mm, Figure 3-5B). 
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Responses at the outlet are in the 200–700 nM range, whereas the in vivo responses are in the 5–
20 μM range. Thus, the in vivo recovery ratio of evoked DA is on the order of 5%. 
 
 
Figure 3-5.  
Evoked DA (mean ± SEM) measured (A) at the probe outlet after 5 days of DEXretro (n = 6, data from Figure 3-3C) 
and (B) directly in the striatal tissue (n = 18: Figure 3-S1 data combined). (C) Response amplitudes normalized with 
respect to the pre-nomifensine amplitude. Statistical analysis was by a two-way ANOVA for location (outlet, tissue) 
and drug (nomifensine, nomifensine/raclopride; repeated measurements). Only the drug was a significant factor 
(F(1,22) = 16.99, p < 0.001): neither location nor interaction were significant. 
 
Because of our new ability to record outlet responses without the aid of nomifensine, it is 
now possible to report the amplitude of both the outlet and in vivo responses normalized with 
respect to their pre-nomifensine amplitudes (Figure 3-5C). We found no significant differences 
between the normalized outlet and normalized in vivo responses (statistical details are in the 
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figure legend). Thus, Figure 3-5C indicates essentially perfect quantitative agreement between 
the outlet and in vivo responses. 
Figure 3-5C represents the first occasion upon which we have been able to report near-
perfect quantitative agreement between evoked responses recorded at the outlet of probes and in 
the tissue adjacent to the probes. Prior studies have consistently found that uptake inhibition 
increases the in vivo recovery of DA.11, 22-24, 34, 40, 58, 119, 138 On theoretical grounds, we suggested 
that the impact of DAT inhibition on the in vivo recovery of DA is indicative of the presence of a 
zone of disrupted tissue adjacent to the probe wherein DA uptake exceeds DA release.58-60 Figure 
3-5 strongly suggests that this zone of disrupted tissue is no longer present under the conditions 
of these measurements, strongly suggesting that the combination of a 5-day postimplantation 
interval with continuous retrodialysis of DEX vastly reduces the effects of the penetration injury. 
3.2.4 In Vivo Voltammetry Next to the Probe 
A second series of experiments was performed to directly assess the impact of DEXretro 
on evoked DA release activity in the tissue surrounding the probe. Five days after probe 
implantation, evoked DA responses were recorded in vivo with two carbon fiber 
microelectrodes. As in a prior study,34 one electrode was placed 1 mm from the probe, and the 
other was placed 100 μm from the probe (Figure 3-6A and C). Without DEXretro, the evoked 
responses 100 μm from the probe were either abolished or significantly reduced (Figure 3-S4), 
consistent with prior observations at 4 and 24 h after implantation.34 However, with DEXretro 
there were no significant differences between the response amplitudes measured 1 mm and 100 
μm from the probe (Figure 3-6B). 
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Figure 3-6.  
(A) Electrolytic lesion confirmed the placement of a carbon fiber electrode 100 μm from the microdialysis probe by 
applying a current of 20 μA for 5 s to the electrode. The white box in the left image is magnified on the right. Scale 
bars are 500 μm (left) and 100 μm (right). (B) Evoked release (mean ± SEM, n = 4 per group) measured 100 μm 
(pattern) and 1 mm (solid) away from the probe after 5 days of DEXretro (responses in Figure 3-S4). Statistical 
analysis was by two-way ANOVA for the drug (pre-nomifensine, nomifensine, and nomifensine/raclopride; 
repeated measurements) and location (100 μm, 1 mm). The drug was significant (F(1,6) = 23.02, p < 0.005), while 
the location and the interaction were not significant factors. (C) Schematic of voltammetry next to the probe with the 
electrodes represented by blue boxes and the probe by a red circle. The adjacent electrode was implanted at a 5° 
angle to allow the tip of the electrode to be placed 100 μm from the probe. 
 
In our prior study at 4 and 24 h after probe implantation,34 evoked responses in close 
proximity to probes perfused with DEX (probe–electrode separation of 100 μm) were detectable 
but significantly lower in amplitude than normal. Thus, Figure 3-6 clearly indicates that 
combining a 5-day postimplantation wait time with continuous DEXretro leads to a reinstatement 
of normal evoked DA activity in close proximity to the probe. 
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3.2.5 DA Kinetic Analysis 
Additional responses were recorded 1 mm and 100 μm from the probe using a 3-s 
stimulus delivered at 60 Hz. The responses underwent kinetic analysis with the numerical model 
of Walters et al.139 The model provides excellent fits to responses recorded 100 μm away with 
DEXretro and to responses 1 mm away either with or without DEXretro (Figure 3-7). Moreover, 
there were no significant differences between the kinetic parameters providing best fits to these 
responses (Table 3-S1). Thus, after 5 days of continuous DEXretro, we detect no significant 
alterations in the kinetics of DA release, uptake, or transport in close proximity to the 
microdialysis probes. 
 
 
Figure 3-7.  
Evoked release (mean, n = 4 per group) measured 1 mm away without (green) and with (orange) DEXretro, and 100 
μm from the probe with DEXretro (blue): error bars are omitted for clarity. The stimulus in this case was for 3 s 
(marked by the horizontal black bar) at 60 Hz. The black lines report the average of the model fits to each individual 
response. The average values of the kinetic parameters (see Table 3-S1) exhibited no significant differences 
(multivariate ANOVA, Pillai’s Trace). The inset shows the response amplitudes, which are not statistically different 
(one-way ANOVA). 
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3.2.6 Immunohistochemistry 
Horizontal tissue sections (35 μm thick) containing the probe tracks were immunolabeled 
for TH and DAT, two widely accepted markers of DA terminals (Figures 3-S5 and 3-S6), and for 
ED-1, a marker of microglia and macrophages.140, 141 The images were quantified by the pixel 
counting routines built into Metamorph (see Methods). 
Images of TH and DAT immunoreactivity in tissues surrounding the tracks of probes 
perfused for 5 days with or without DEXretro were indistinguishable from each other and from 
images of nonimplanted control tissue (Figure 3-8). All images exhibited extensive 
immunoreactivity except in locations corresponding to myelinated axon bundles, blood vessels, 
and the probe tracks: all such features were clearly visible in DIC images of the same tissues. 
Quantitative image analysis produced no significant differences among these images (ANOVA 
details are in the figure legend). Images at higher magnification (40, 60, and 100×) indicate 
punctate TH labeling up to the very edge of the probe tracks (Figure 3-S7). 
 
 44 
 
Figure 3-8.  
DAT (blue) and TH (red) immunoreactivity in tissue sections containing tracks of probes perfused without (left) and 
with (right) DEXretro for 5 days and in sections of nonimplanted control tissue (center). Asterisks mark the center of 
the probe tracks. Scale bar = 100 μm. The bottom graph shows the quantification of the fluorescent pixels for each 
marker: the probe tracks were excluded from the regions of interest. In a 2-way ANOVA of treatment (aCSF, DEX, 
and control) and antibody (TH and DAT), neither the treatment nor the antibody was a significant factor. 
 
These findings stand in stark contrast to our observations of marked disruptions of TH 
immunoreactivity near probe tracks at 4 and 24 h after implantation, especially when DEXretro 
was absent.33, 34 The reinstatement of normal TH and DAT immunoreactivity appears to be in 
excellent agreement with the reinstatement of evoked DA activity in close proximity to the 
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probes (Figures 3-2 through 3-6). However, images of TH and DAT immunoreactivity near 
probes perfused without DEX also appear similarly normal, which comes as a surprise because 
evoked DA release adjacent to and at the outlet of these probes show major disruptions (Figure 
3-2 and 3-S4). Thus, the ability of 5 days of DEXretro to reinstate normal evoked DA release 
activity cannot be attributed solely to the reinstatement of normal TH and DAT 
immunoreactivity. 
During previous work, we showed that 5 days of DEXretro is highly effective at 
suppressing the activation of astrocytes and preventing the formation of a glial scar at the probe 
track31 (see also Figure 3-S8). Here, we document that DEXretro is likewise highly effective at 
suppressing the activation of microglia (Figure 3-9). Thus, our histochemical findings suggest 
that the reinstatement of normal TH and DAT immunoreactivity in close proximity to the probes 
is necessary but not sufficient for reinstatement of evoked DA release activity, as suppression of 
gliosis and scar formation is also critical. 
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Figure 3-9.  
Immunoreactivity for ED-1 in sections containing the tracks of probes without (left) or with DEXretro (right) and 
sections from nonimplanted control tissue (center) (asterisks represent the center of the probe track, scale bar = 100 
μm). The bottom graph compares counts of ED-1 positive cells in area matched sections of aCSF, DEXretro, and 
control tissue. Statistical analysis was by one-way ANOVA, F(2,22) = 21.560, p < 0.001. Asterisks report the 
posthoc tests (Games–Howell). *p < 0.05, **p < 0.01, and ***p < 0.005. 
3.3 CONCLUSIONS  
Our findings confirm that combining a 5-day postimplantation wait period with 
concurrent and continuous DEXretro vastly reduces the effects of the penetration injury at the 
microdialysis probe track. This enables the recording of robust and reproducible evoked DA 
responses at the probe outlet, which can be attributed to a reinstatement of normal evoked DA 
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activity in the tissues in close proximity to the probes. Furthermore, the reinstatement of normal 
evoked DA activity adjacent to the probes blocked nomifensine’s ability to alter the in vivo 
microdialysis recovery of DA, a phenomenon previously attributed to a zone of disrupted tissue 
at the probe track.58-60 Overall, combining a 5-day postimplant interval with DEXretro brings 
evoked DA responses at the probe outlet into excellent quantitative agreement with in vivo 
responses. In our line of investigation into these matters, this is the first occasion upon which we 
have observed such excellent agreement. The efficacy of DEX in this work appears to be due to 
its anti-inflammatory actions, as markers of DA terminals appear normal upon histochemical 
examination after 5 days regardless of whether DEXretro was performed. Thus, the reinstatement 
of normal TH and DAT immunoreactivity, accepted markers of DA terminals, at the probe track 
is necessary but not sufficient for the reinstatement of normal evoked DA release activity, as 
suppression of gliosis and scarring is also critical. 
Our conclusion that the postimplantation wait period is an important contributor to the 
reinstatement of DA function in close proximity to the probe concurs with the work of Di Chiara 
and colleagues.142-144 In their work, histology after several weeks of repetitive probe insertions 
through a guide cannula shows the presence of TH-positive varicosities and no signs of 
necrosis.142-144 This concurs with our finding (Figure 3-8) that DA terminals appear normal as 
early as 5 days after probe implantation. However, our findings show that gliosis is also an 
important consideration. 
The choice of dexamethasone as an anti-inflammatory agent raises some potentially 
contentious issues as steroids have their own neurochemical actions.145 During this work, we 
found no evidence that dexamethasone altered evoked DA release, which is consistent with a 
body of literature indicating that DA systems are not highly sensitive to steroids.146-150 Thus, the 
 48 
effects of DEX described above appear to reflect anti-inflammatory rather than neurochemical 
mechanisms. However, DEX might prove unsuitable in some microdialysis investigations of 
other neurochemical systems that exhibit greater sensitivity to steroids. In this light, it is relevant 
to mention that alternatives to DEX are available, including nonsteroidal anti-inflammatory 
drugs. It is also worth mentioning that retrodialysis, even over extended time periods, involves 
truly minuscule quantities of drug: the total amount of dexamethasone delivered via retrodialysis 
during the experiments reported here is less 20 nanomoles. While alternative anti-inflammatory 
strategies (agent, dose, duration, etc.) remain to be explored, we believe that this work clearly 
establishes the overall principle of anti-inflammatory enhanced microdialysis. 
3.4 METHODS 
All use of animals was approved by the University of Pittsburgh Institutional Animal 
Care and Use Committee. Some of the methods and procedures employed for the present study 
have been previously described.11, 34 
3.4.1 Reagents and Solutions 
All solutions were prepared with ultrapure water (Nanopure; Barnstead, Dubuque, IA). 
Artificial cerebrospinal fluid (aCSF: 142 mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 mM 
MgCl2, and 2.0 mM NaH2PO4, pH 7.4) was used for voltammetric DA calibration and as the 
perfusion fluid of the microdialysis probe. Dexamethasone sodium phosphate (APP 
Pharmaceuticals LLC, Schaumburg, IL) was diluted in aCSF. The perfusion fluids for 
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microdialysis were filtered with Nalgene sterile filter units (Fisher, Pittsburgh, PA; PES 0.2 μm 
pores). Nomifensine maleate and S(−)raclopride (+)-tartrate (Sigma-Aldrich, St. Louis, MO) 
were dissolved in phosphate-buffered saline (PBS: 137 mM NaCl, 2.7 mM KCl, 1.47 mM 
KH2PO4, and 10 mM Na2HPO4, pH 7.4) and administered at 20 mg/kg and 2 mg/kg (i.p.), 
respectively. DA (Sigma-Aldrich, St. Louis, MO) standards were prepared in N2-purged aCSF 
for electrode calibration. 
3.4.2 Microdialysis Probes and DEXretro 
Concentric-style microdialysis probes (300 μm in diameter, 4 mm membrane length) 
were built in-house (13 kDa MWCO Spectra/Por hollow fiber, Spectrum Laboratories Inc. 
Rancho, Dominquez, CA). Fused silica capillaries (75 μm I.D., 150 μm O.D., Polymicro 
Technologies, Phoenix, AZ) were used for the inlet and outlet lines. The probe inlet was 
connected to a syringe pump (Harvard Apparatus, Holliston, MA) running at 0.610 μL/min. The 
outlet capillary was 10 cm long. Prior to use, the probes were soaked in 70% ethanol and then 
immersed in and flushed with filtered perfusion fluid for several hours before implantation 
(aCSF or aCSF with DEX). During procedures involving DEXretro, the probe was perfused first 
with 10 μM DEX for 24 h and thereafter with 2 μM DEX, as previously described.31 When DEX 
was used, it was added to the perfusion fluid prior to probe implantation. 
3.4.3 Voltammetry 
Carbon fiber electrodes were constructed by placing a single carbon fiber (7 μm diameter, 
T650, Cytec Carbon Fibers LLC., Piedmont, SC) in a borosilicate capillary (0.58 mm I.D., 1.0 
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mm O.D., Sutter Instruments, Novato, CA), pulling the capillary to a fine tip (Narishing Tokyo, 
Japan), sealing the tip with a low viscosity epoxy (Spurr Epoxy, Polysciences Inc., Warrington, 
PA), and trimming the exposed fiber to 400 or 800 μm for in vivo and outlet recordings, 
respectively. FSCV was performed with a potentiostat (EI-400, Ensman Instruments, 
Bloomington, IN) and CV Tarheel software (version 4.3, Michael Heien, University of Arizona, 
Tucson AZ). The waveform began at the rest potential of 0 V, scanned to +1.0 V, then to −0.5 V, 
and back to the rest potential at 400 V/s: potentials are vs Ag/AgCl. Scans were performed at 2.5 
Hz during the 25-s stimulations and 10 Hz for the 3-s stimulations. The 800 μm outlet electrodes 
were pretreated (0–2 at 200 V/s for 3 s) 10 min before each stimulus or calibration procedure. 
This pretreatment improves sensitivity but also causes some drift in the FSCV background 
signal, which is noticeable at low DA concentrations (∼20–30 nM).23 To minimize the drift, the 
pretreatment was followed by application of the FSCV waveform at 60 Hz for 120 s. 
3.4.4 Voltammetry at the Microdialysis Probe Outlet 
The outlet capillary was passed through the floor of a Plexiglas electrochemical cell. The 
microelectrode for FSCV at the outlet was inserted into the capillary end with a miniature 
micromanipulator (Fine Science Tools, Foster City, CA). To confirm the performance of the 
probe and the electrode, calibration was performed by exposing the probe to a 10 μM DA 
solution for 30 s prior to animal use. 
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3.4.5 Surgical and Stimulation Procedures 
Prior to surgery, rats (male Sprague–Dawley, 250–350 g, Charles River, Raleigh, NC) 
were acclimated overnight to a Raturn Microdialysis Bowl (MD-1404, BASI, West Lafayette, 
IN). The next day, the rats were anesthetized with isoflurane (5% induction, 2.5% maintenance) 
and implanted with microdialysis probes following aseptic stereotaxic surgical technique. Using 
flat skull coordinates,151 the probes were slowly lowered into the striatum (1.6 mm anterior, 2.5 
mm lateral from bregma, and 7.0 mm below the dura) at 5 μm/s using a micropositioner (David 
Kopf Instruments, Tujunga, CA). Probes were secured with bone screws and acrylic cement and 
the incision was closed with sutures (there was no guide cannula). Anesthesia was removed and 
animals were returned to the Raturn system and given free access to food and water. 
After 5 days, the rats were reanesthetized and returned to the stereotaxic frame, where 
they remained for the duration of all procedures. A reference electrode was contacted to the brain 
surface with a salt bridge, a carbon fiber microelectrode was inserted into the striatum 1.5 mm 
away from the probe (0.45 mm anterior to bregma, 3.5 mm lateral from bregma, and 5.0 mm 
below dura), and a bipolar stimulating electrode was lowered into the medial forebrain bundle 
ipsilateral to the probe and carbon fiber microelectrode (4.3 mm posterior from bregma, 1.2 mm 
lateral from midline, and 7.2 mm below the dura). The stimulus waveform was a biphasic, square 
wave with constant current pulses (300 μA pulse height and 4 ms pulse width). The waveform 
was delivered for 25 s at 45 Hz or 3 s at 60 Hz. Nomifensine and raclopride were sequentially 
administered (i.p.), and evoked DA responses were recorded 20 min after each drug 
administration. A second series of evoked responses were recorded in the tissue next to the 
probes with carbon fiber electrodes placed 1 mm and 100 μm from the probes, as previously 
described.34 
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At the end of the experiment, while the rats were deeply anesthetized, the locations of the 
carbon fiber electrodes were marked with a current lesion (20 μA for 5 s) just before the rats 
were perfused through the heart to preserve the brain for subsequent analysis.31 
3.4.6 Area under the Curve (AUC) Analysis 
The responses measured at the probe outlet (black line, Figure 3-S3) underwent an AUC 
analysis. If the response exhibited baseline drift, as discussed above, the drift was measured and 
subtracted (purple line, Figure 3-S3). Next, we applied the “hang-up” correction described 
elsewhere139 (green line, Figure 3-S3). The AUC was determined with MATLAB’s trapezoidal 
integration function in units of micromolar and seconds. 
3.4.7 Immunohistochemistry 
Horizontal tissue sections (35 μm thick) were prepared in a cryostat and stored at −20 °C 
until further use. Tissue sections were hydrated in PBS, blocked with 20% normal goat serum, 
1% bovine serum albumin, and 0.3% Triton X (Sigma) in PBS (2.5 h). Sections were then 
incubated with primary antibodies for TH (1.5:1000, Millipore, Temecula, CA), DAT (1:400, 
Synaptic Systems, Göttingen, Germany), or ED-1 (for activated microglia/macrophages, CD68, 
1:100, AbD Serotec, Raleigh, NC). Secondary antibodies were goat anti-rabbit IgG, CY3 
(Invitrogen, USA) for TH, while ED-1 and DAT used goat anti-rabbit IgG Cy5 (Invitrogen, 
USA). Secondary antibodies were diluted 1:1000 in blocking solution. Sections were rinsed in 
PBS (3 × 5 min) and coverslips added with Fluoromount-G (Southern Biotechnology Associates, 
Birmingham, Alabama). 
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3.4.8 Fluorescence Microscopy and Image Analysis 
Fluorescence microscopy (Olympus BX61, Olympus; Melville, NY) was performed with 
a 20, 40, 60, and 100× objective using appropriate filter sets (Chroma Technology; Rockingham, 
VT). The Metamorph/Fluor 7.1 software package (Universal Imaging Corporation; Molecular 
Devices) was used to collect, threshold, analyze, and quantify the images. The numbers of ED-1 
positive cells in the section of the tissue surrounding the microdialysis track were counted. The 
number of fluorescent pixels in the TH and DAT images was expressed as a percent of pixels in 
the region of interest, which excluded the probe track. A minimum of 3 animals per group with 3 
slices per brain were used for the statistical analysis. 
3.4.9 Statistics 
IBM Statistical Package for the Social Sciences (SPSS) 22 software was used for all 
statistical analysis. For ANOVA, SPSS was used to check for parameter normality and equality 
of variance. For statistical significance, p < 0.05 was used for all tests. 
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3.5 SUPPORTING INFORMATION 
 
 
Figure 3-S1. 
Amplitude (mean ± SEM, n = 6 per group) of evoked responses measured with FSCV at microelectrodes placed in 
the striatum 1.5 mm away from the microdialysis probes. A two-way ANOVA was performed with time (24 hr, 5 
days) and treatment (aCSF, DEX) as the classifications: time, treatment, and interaction were not significant factors 
(p > 0.05). 
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Figure 3-S2. 
Evoked responses (mean ± SEM, n = 6 per group) measured after administration of nomifensine and raclopride at 
the microdialysis probe outlet 4 hr (blue) and 5 days (red) after probe implantation. This data is a representation of 
the notably broader responses observed after 5 days. The exact reasons underlying the changes in the temporal 
features of the response over time are unknown. 
 
 
Figure 3-S3. 
A representative data set to illustrate the area-under-the-curve procedure explained in the methods section. The raw 
data (black) exhibits baseline drift, which is corrected by subtraction (purple). The hang-up correction procedure139 
is applied after the baseline subtraction (green). The area under the green curve is determined by numerical 
integration. 
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Figure 3-S4. 
Evoked responses (mean ± SEM, n=4 per group) to a pre-nomifensine stimulation measured simultaneously at two 
carbon fiber electrodes in the striatum. Black diamonds mark the start and end of stimulation. The curves are 
represented as percentage of the 1 mm away response (green line) for both A) aCSF and B) DEXretro treated rats. 
With DEXretro the responses were comparable (see Figure 3-6B). However, without DEXretro evoked dopamine was 
either abolished (3 of 4 rats) or significantly reduced (1 of 4 rats) adjacent to the probe (pink line) (t(5)=0.347, 
p<0.005). In 1 of the 4 animals without DEXretro the response was reduced but measurable adjacent to the probe, and 
in this case the lesion confirmed the electrode was placed slightly further from the probe. 
 
 
Figure 3-S5. 
Striatal tissue labeled with TH. A) This image of TH labeling at the edge of the striatum shows that only the striatal 
portion of the section is labeled. B) This is an image of nanobeads in blood vessels. C) This image is the overlay of 
the TH and the nanobead images from A and B. D) This is the corresponding DIC image. Similar images were 
obtained for DAT labeling. Scale bar is 100 μm. 
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Figure 3-S6. 
Images of a horizontal tissue section (35 μm thick) containing a probe track labeled for TH immunoreactivity (red, 
A) and for blood vessels (green, B). The overlay image (C) shows TH and blood vessels in close proximity to the 
probe track. D) is the DIC image of the same section. 
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Figure 3-S7. 
Fluorescence microscopy of TH labeling around a probe track (A) at three magnifications (B, C, and D). Punctate 
labeling near the probe track is visible at the higher magnifications. 
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Figure 3-S8. 
Fluorescence microscopy of tissue perfused for 5 days without DEXretro (top) and with DEXretro (bottom). Sections 
were labeled with GFAP (A and C) and nanobeads (B and D). Asterisks represent the center of the probe track. 
Scale bar = 100μm. 
 
 
Table 3-S1. 
Four adjustable parameters obtained through fitting the data in Figure 3-7 with the restricted diffusion model 
previously described.1 The parameters are Rp for the kinetics of DA release, kU for the kinetics of uptake, kT 
represents mass transport (restricted diffusion), and kR is a short term plasticity factor modifying the rate of release. 
Through analysis of the four parameters there was no significant difference in the model fits of the three curves 
(multivariate ANOVA: Pillai’s Trace, F (8,14)=1.021, p>0.05). 
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4.0  ENHANCING CONTINUOUS ONLINE MICRODIALYSIS USING 
DEXAMETHASONE: MEASUREMENT OF DYNAMIC NEUROMETABOLIC 
CHANGES DURING SPREADING DEPOLARIZATION 
Reprinted with permission from Varner, E.L., Leong, C.L., Jaquins-Gerstl, A., Nesbitt, 
K.M., Boutelle, M.G., Michael, A.C., ACS Chem. Neurosci. 2017, Article ASAP, 
DOI: 10. 1021/acschemneuro.7b00148. Copyright 2017 American Chemical Society. 
 
Dr. Andrea Jaquins-Gerstl contributed the immunohistochemistry and fluorescence 
microscopy work presented in this chapter. The Boutelle group designed the K+ and glucose 
detection systems and Dr. Chi Leng Leong trained Andrea and I on the systems.  
4.1 INTRODUCTION 
The high incidence of traumatic brain injury (TBI) is a significant health crisis, described 
recently as a “silent epidemic”.61, 62 In the United States, 1.7 million brain injuries per year lead 
to 275 000 hospitalizations and 52 000 deaths.63 The heart of the problem is secondary brain 
injury, which can cause death many days after the primary TBI even though the patient is under 
intensive care. Secondary injury occurs when the so-called penumbra is subjected to secondary 
insults, such as high intracranial pressure, transient ischemia, seizures, and spreading 
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depolarization (SD). Neuromonitoring after severe TBI detects SD64-66, 152-154 in approximately 
60% of patients.68-71 SD is a pathological mechanism for secondary injury that drives expansion 
of the brain lesion into the penumbra.66-71, 155 Incidence of SD is significantly correlated with 
poor patient outcomes, including death, vegetative state, and severe disability.64-66 SD disrupts 
the concentration gradients of ions and molecules between intra- and extracellular spaces, and 
repolarization after SD requires vast amounts of energy. 64-66 Clusters of SD impose particularly 
severe energy demands on the injured brain.16, 67, 72, 73 
Microdialysis is well-established for real time intracranial chemical monitoring.3, 4 
Clinical microdialysis facilitates monitoring of the local metabolic status of brain tissue in 
patients with TBI.16, 17, 75, 77, 78, 156, 157 Boutelle and co-workers developed a rapid sampling 
microdialysis (rsMD) system that monitors glucose with 30 s temporal resolution.75 By the 
combination of rsMD with an online ion selective electrode (ISE), simultaneous rapid 
monitoring of glucose and K+ is now possible.76-78 
Nevertheless, inserting a microdialysis probe into brain tissue causes a penetration 
injury.25-28, 31-34 The brain wound response produces a barrier of abnormal tissue that surrounds 
the microdialysis probe, thereby impairing microdialysis sampling.22, 31, 35-39 Emerging evidence 
suggests that retrodialysis of dexamethasone (DEX), a glucocorticoid anti-inflammatory steroid, 
is a simple yet effective strategy for mitigating the probe penetration injury. Recent work on the 
microdialysis of dopamine in the rat striatum shows that DEX reduces ischemia, suppresses glial 
activation, protects neurons and neuronal terminals, prevents the formation of a glial barrier, and 
reinstates normal dopamine activity in the tissues surrounding microdialysis probes.31-35  
Here, we report that DEX offers similar benefits to the microdialysis monitoring of SD-
induced glucose and K+ transients in the rat cortex. We inserted microdialysis probes, with and 
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without retrodialysis of DEX, and monitored SD-induced glucose and K+ transients 2 h, 5 days, 
or 10 days later. Retrodialysis of DEX improved the detection of SD-induced transients at all 
three time points. In our 10-day studies, DEX retrodialysis was performed only during the first 5 
days, confirming that continuous DEX delivery for the entire 10-day time window is not 
required. Finally, after retrodialysis of DEX, histochemical inspection of probe tracks found no 
signs of ischemia or gliosis 10 days after insertion. Our findings confirm that DEX enhances the 
performance of microdialysis for monitoring SD-induced glucose and K+ transients in the rat 
cortex for at least 10 days after probe insertion. 
4.2 RESULTS AND DISCUSSION 
4.2.1 Experimental Design 
Microdialysis probes were inserted into the rat cortex and used to monitor K+ and glucose 
in response to SD triggered by needle pricks 2 h, 5 days, or 10 days later. Due to the design of 
the experiments, different animals were used at each time point. For observations at 2 h after 
probe insertion, the animals were anesthetized for probe insertion and remained anesthetized for 
the duration of the experiment. For observations at 5 and 10 days after probe insertion, the 
animals were anesthetized for probe insertion, allowed to recover from anesthesia, housed in a 
Raturn system, and then reanesthetized for the measurements. The anesthetic was isoflurane. 
Once inserted, all probes were perfused continuously at 1.67 μL/min, with only occasional brief 
interruptions to refill the perfusion syringe. The probes were perfused with artificial 
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cerebrospinal fluid (aCSF) either with or without DEX. The concentration of DEX was 10 μM 
for the first day of perfusion, 2 μM for days 1–5, and zero for days 5–10.31, 35 
Glucose and K+ were monitored with rsMD and an online ISE, respectively, as 
previously described (Figure 4-1).76 In vitro probe recovery was 64.0 ± 1.5% for K+ and 10.1 ± 
0.6% for glucose (mean ± SE). The higher recovery for K+ is due to its small size compared to 
glucose. Probe recovery was constant when probes were stored in aCSF for 10 days (Table 4-
S1). Dialysate concentrations reported herein have not been corrected for probe recovery. 
 
 
Figure 4-1. 
Experimental design. SD was induced by needle pricks in the cortex. The SD arrives at the microdialysis probe at t0: 
intervals between the needle pricks and t0 were typically less than 1 min. Next, the sample travels to the K+ ISE in 
approximately 4 min, t1. Finally, the sample travels to the glucose detector in approximately 7 min, t2. Recordings of 
K+ and glucose in Figures 4-2 through 4-6 are time-adjusted to account for t1 and t2. 
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4.2.2 Probe Insertion and Representative Observations 
Figure 4-2 shows an example of a complete recording of K+ and glucose from an acute 
experiment in a single rat. Prior to probe insertion the dialysate K+ and glucose concentrations, 
2.7 mM and zero, respectively, derive from the perfusion fluid. In Figure 4-2, and all subsequent 
figures, the K+ and glucose traces are time-adjusted according to t1 and t2 (see Figure 4-1) so that 
the transients are aligned in time with each other and with the needle pricks. The vertical black 
lines show when the needle pricks were performed. The delay time between the needle pricks 
and the time-adjusted K+ transients, which begin at t0 (Figure 4-1), was typically less than 1 min. 
Each needle prick induced a clear K+ spike and a clear glucose dip. The spike in K+ is a hallmark 
feature of SD and the glucose dip is indicative of the energy consumed as the tissue repolarizes 
after SD. 
 
 
Figure 4-2. 
Representative complete recording of K+ (purple) and glucose (red) from an acute experiment performed in one rat. 
The microdialysis probe was inserted at time 0 with DEX perfusion. Then, 2 h later, three needle pricks were 
performed 30 min apart (black lines mark when the needle pricks occurred). The K+ and glucose traces have been 
time-adjusted to account for t1 and t2 (defined in Figure 4-1). 
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A prominent K+ spike also occurred just after the microdialysis probe was inserted into 
the cortex (Figure 4-2). A few moments later, the glucose signal, which had been initially 
increasing toward a basal level, also dipped. This initial K+ spike and glucose dip, which we 
attribute to SD triggered by the penetration injury during probe insertion,22, 25-28, 31-39 were 
observed in all animals regardless of whether or not the perfusion fluid contained DEX (Figure 
4-3). 
 
 
Figure 4-3. 
Probe insertion SD in the rat cortex characterized by (A) an increase in K+ (K+ spike) and (B) a decrease in glucose 
(glucose dip) time-aligned to the probe insertion at time zero (mean ± SEM, n = 16 rats). In this figure, t = 0 is the 
time at which probe insertion was completed: note, however, that recovery of K+ and glucose begins as soon as the 
probe contacts brain tissue. 
 
In the case of Figure 4-2, after the insertion SD the dialysate glucose concentration 
increased quickly at first, stabilized, and then increased slowly but continuously until the needle 
pricks began. All animals exhibited some combination of drift and noise in the glucose baseline 
but there were no consistent trends between animals prior to the needle pricks. 
Two additional examples of complete recordings of K+ and glucose from single animals 
are provided in the Supporting Information. Figure 4-S1 is an example with needle pricks that 
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produced neither a K+ spike nor a glucose dip. Of the 104 needle pricks performed during this 
work, only 11 (∼11%) produced neither a K+ spike nor a glucose dip. We assume that the needle 
prick either did not induce SD or that SD did not reach the location of the microdialysis probe. 
When this occurred, extra pricks were performed so that three SD responses were recorded from 
each animal. In Figure 4-S1, the needle pricks triggered a slow decline in the basal glucose level 
in addition to the glucose dips. A similar event was noted in 65% of the animals included in this 
study. Previous studies have a reported similar observations.16, 17 
Figure 4-S2 shows a unique adverse event: in this one animal, the needle prick induced a 
long-lasting elevation in K+ and a long-lasting decline in glucose. The rat died about 1 h later. 
This unique event resembles a phenomenon called spreading ischemia,158 although without direct 
measurement of blood flow this cannot be confirmed. 
4.2.3 SD-Induced Transients 2 h after Probe Insertion 
Three needle pricks were performed at 30 min intervals beginning 2 h after insertion of 
microdialysis probes into the rat cortex. DEX increased the amplitudes of the SD-induced K+ 
spikes and glucose dips by 127% and 86% (averages of the three responses), respectively, 
compared to those observed without DEX (Figure 4-4: DEX also significantly increased the 
areas-under-the-curves, see Figure 4-S3). The amplitudes of the K+ spikes and the glucose dips 
consistently decreased upon each consecutive needle prick (Figure 4-4) but this trend did not 
reach statistical significance (see the figure legend for the ANOVA details). We speculate this 
decreasing trend is a consequence of repetitively pricking the same cortical location. 
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Figure 4-4. 
Cortical responses to three needle pricks recorded 2 h after probe insertion with (A) aCSF or (B) DEX (mean ± 
SEM, n = 8 rats (24 needle pricks) per group). Maximum changes in (C) K+ and (D) glucose were analyzed with 
two-way ANOVAs with group (aCSF, DEX) and needle prick (1, 2, 3; repeated measures) as the factors. The needle 
prick and interactions were not significant, but group was significant for both K+ (F(1,14) = 13.422) and glucose 
(F(1,14) = 6.253). **p < 0.005, *p < 0.05. 
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4.2.4 SD-Induced Transients 5 Days after Probe Insertion 
Probes were inserted and perfused with aCSF or DEX for 5 days. Then, rats were 
reanesthetized 1 h before the first needle prick. If a needle prick produced neither a K+ spike nor 
a glucose dip, an extra needle prick was performed, as explained above. In some cases, however, 
the needle prick produced a K+ spike but no detectable glucose dip (11 of 15 with aCSF and 3 of 
15 with DEX). Such needle pricks were not repeated: instead, the glucose dip was rated as 
nondetectable. All needle pricks that induced a K+ spike were included in the data analysis 
explained below. 
Glucose dips were rated as nondetectable if their amplitude did not exceed 3× the 
baseline noise. The baseline noise was determined from the standard deviation of the glucose 
concentrations measured over the 10 min interval prior to each needle prick (Figure 4-S4). By 
this procedure, the average glucose detection limit for the five groups in this study was 37 ± 
16 μM (mean ± SE): this value exceeds the rsMD detection limit of 25 μM reported 
previously.159 Thus, the limit of detection in this work is determined by the noise in the glucose 
baseline rather than the noise in the rsMD detector. 
After microdialysis probes were perfused with aCSF for 5 days, the K+ spikes were of 
low amplitude and the glucose dips were essentially nondetectable (Figure 4-5A). Fifteen K+ 
spikes were observed (5 animals, 3 responses each), but only 4 were accompanied by glucose 
dips with amplitudes greater than 3× the baseline noise. As observed at 2 h, the amplitude of the 
consecutive K+ spikes decreased upon each consecutive needle prick (Figure 4-5C), presumably 
due to repetitively pricking the same cortical location. Our previous work shows that 
microdialysis probes are surrounded by a barrier of abnormal tissue by 5 days after insertion,31, 35 
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thus we attribute the low amplitudes of these K+ and glucose transients to the presence of such a 
barrier. 
 
 
Figure 4-5. 
Average cortical response to needle pricks recorded 5 days after probe insertion with (A) aCSF or (B) DEX (mean ± 
SEM, n = 5 rats (15 needle pricks) per group). (C) Changes in K+ to the three needle pricks were analyzed with a 
two-way ANOVA with group (aCSF, DEX) and needle prick (1, 2, 3; repeated measures) as the factors. Group 
(F(1,8) = 5.844, p < 0.05) and needle prick (F(2,16) = 12.689, p < 0.001) are significant, interaction is not 
significant. (D) Only detectable glucose responses are represented in (A) and (B); see Table 4-1 and Figure 4-S4 for 
details. *p < 0.05. 
 
After microdialysis probes were perfused with DEX for 5 days, needle pricks induced 
robust K+ spikes and robust glucose dips (Figure 4-5B). We observed 15 K+ spikes and 12 (80%) 
of these were accompanied by quantifiable glucose dips. Averaging over the three consecutive 
needle pricks, the amplitudes of K+ spikes measured with DEX were 184% larger than those 
measured without DEX (Figure 4-5C). The effect of DEX was significant (ANOVA details in 
the legend of Figure 4-5: statistical analysis of the glucose responses were not possible because 
those measured without DEX were not quantifiable, see Figure 4-5D). We attribute DEX’s 
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ability to enhance the detection of SD-induced transients to its ability to prevent the formation of 
a barrier of abnormal tissue at the probe track, as previously demonstrated.31-35  
4.2.5 SD-Induced Transients 10 Days after Probe Insertion 
Microdialysis probes were inserted into the rat cortex and responses to needle pricks were 
recorded 10 days later. DEX retrodialysis was performed only during the first 5 days. On the 
fifth day the perfusion fluid was switched from DEX to aCSF, which was perfused through the 
probes for the remainder of the experiments. There were two principal reasons for adopting this 
protocol. First, DEX is an exogenous agent. In most instances, whether working in animals or 
patients, it is preferable to use a minimum sufficient quantity of such an exogenous agent. 
Second, prior work on neuroprosthetic devices suggests that continuous delivery of DEX might 
not be necessary for long-term benefits.42, 46, 47 
Needle pricks performed 10 days after probe insertion induced robust K+ spikes and 
corresponding glucose dips (Figure 4-6): 87% of the 15 K+ spikes were accompanied by a 
quantifiable glucose dip (Table 4-1). As observed at 2 h and 5 days, there was a decreasing trend 
in the amplitude of the K+ spikes on each consecutive needle prick. However, no such trend 
appeared in the glucose responses, which exhibited consistent amplitudes. Figure 4-6 confirms 
the benefits of DEX retrodialysis for monitoring SD-induced K+ and glucose transients outlast 
the duration of the DEX retrodialysis itself. Figure 4-6 is our first report of DEX-enhanced 
microdialysis at 10 days after probe insertion. Previously, we showed that 5 days of DEX 
retrodialysis reinstated normal dopamine neurochemical activity near the probe.35 Here we 
extend that work not only to 10 days after probe insertion, a clinically relevant time window, but 
also to include the enhancement of monitoring K+ and glucose transients in the context of SD. 
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Figure 4-6. 
(A) K+ and (B) glucose response (mean ± SEM) to needle pricks performed 10 days after probe insertion (n = 5 rats, 
15 needle pricks). (C) and (D) provide the changes in K+ and glucose, respectively, to each of the three needle 
pricks. Needle prick number was not a significant factor for either K+ or glucose (1-way ANOVAs, repeated 
measures). The microdialysis probe was perfused with DEX for days 1–5 and then aCSF for days 5–10. 
 
 
 
Table 4-1. 
Observation of a K+ spike confirmed SD in the vicinity of the probe. In every case, except for 5 days aCSF, the 
majority of the K+ spikes were accompanied by a quantifiable glucose dip. Only the quantifiable glucose dips are 
included in Figures 4-4 through 4-7. The noise in a 10 min glucose baseline prior to each needle prick was used to 
create a threshold quantifiable glucose value (see text and Figure 4-S4 for details). 
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4.2.6 Quantitative Comparisons 
In the presence of DEX, the amplitudes of the K+ spikes were significantly larger at 2 h 
compared to 5 and 10 days (Figure 4-7A). In contrast, there were no significant differences 
between the amplitudes of the glucose dips at the three time points (Figure 4-7B). In the presence 
of DEX, the fraction of K+ spikes accompanied by quantifiable glucose dips was relatively 
constant across the three time points (Table 4-1). In the absence of DEX, glucose dips were 
essentially nondetectable 5 days after probe insertion (Table 4-1). 
 
 
Figure 4-7. 
Summary comparison (mean ± SEM) of the amplitudes of (A) K+ spikes and (B) glucose dips in response to three 
needle pricks recorded 2 h, 5 days, and 10 days after probe insertion in the presence of DEX. Data were analyzed 
with two-way ANOVAs with time (2 h, 5 days, 10 days) and needle prick (1, 2, 3; repeated measures) as the factors. 
K+: time is significant (F(2,15) = 15.878, p < 0.0005 while needle prick and the interaction are not significant. 
Glucose: neither factor was significant. Stars represent Games-Howell posthoc tests, **p < 0.001 and *p < 0.005. 
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Prior to the start of the needle pricks the basal K+ and glucose concentrations were 3.1 ± 
0.1 mM and 374 ± 36 μM, respectively (mean ± SE, n = 31 animals). There were no significant 
differences between the basal levels of the 5 groups analyzed in this study (one-way ANOVAs). 
This confirms that none of the probes failed during this study, including those perfused for 5 
days without DEX. 
4.2.7 Immunohistochemistry 
We used fluorescence microscopy to examine thin sagittal sections of brain tissue 
containing the tracks of probes implanted for 10 days. Nonimplanted control tissues from the 
contralateral hemisphere were used for comparison. When probes were perfused with DEX for 5 
days after probe insertion, immunohistochemistry showed no evidence of ischemia (lack of 
nanobeads) or gliosis (GFAP) 10 days after probe insertion (Figure 4-8). When the percent of 
fluorescent pixels in images of probe tracks were compared to images of nonimplanted control 
tissue, there were no significant differences between either the blood flow or gliosis images 
(Figure 4-8D,H: during the analysis the probe tracks were excluded from the regions of interest). 
Figure 4-8 extends our previous reports that DEX prevents ischemia and gliosis.31, 33 
Figure 4-8 is our first report that DEX prevents ischemia and gliosis near probes inserted 
into the rat cortex, that the benefits of DEX last for 10 days after insertion, and that the benefits 
of DEX retrodialysis long outlast the DEX retrodialysis itself. 
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Figure 4-8. 
Representative fluorescent microscopy images of the probe tracks after 10 days. The cortex is labeled for (A,B) 
blood flow (fluorescent nanobeads) and (E,F) GFAP immunoreactivity. The left column (A,E) is control, 
nonimplanted cortex tissue from the contralateral hemisphere. The center column (B,F) is tissue surrounding the 
microdialysis probe 10 days after probe implantation (5 days of DEX). The DIC images (C,G) are provided to 
identify the location of the microdialysis probe tracks in (B) and (F). Graphs comparing the (D) blood flow and (H) 
GFAP immunoreactivity in the areas of interest in both the ipsilateral and contralateral hemispheres. There is no 
significant difference between probe tracks and control tissue for either nanobeads or GFAP (t tests). Results are 
reported as the percent of fluorescent pixels (mean ± SEM). Scale bar is 100 μm. 
 
4.3 CONCLUSIONS 
Our findings confirm that DEX retrodialysis enhances the microdialysis detection of SD-
induced K+ and glucose transients for at least 10 days after probe insertion. We observed an 
insertion SD (Figures 4-2 and 4-3), supplementing prior evidence that insertion causes a 
penetration injury.22, 25-28, 31-39 Despite the penetration injury, brain microdialysis is well tolerated 
by animals and human patients alike, presumably because only a small volume of tissue is 
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affected. The issue at hand, however, is the impact of the penetration injury-induced ischemia, 
cell loss, gliosis, and glial barrier formation on the outcome of brain microdialysis sampling.25-28, 
31-35 Thus, our objective is to promote the recovery of normal brain function and activity at the 
probe site. Retrodialysis of DEX is emerging as a simple yet effective strategy for achieving this 
objective. 
Without DEX, SD-induced transients became difficult to monitor 5 days after probe 
insertion. K+ transients exhibited a significant decrease in amplitude and glucose transients 
became too small to reliably quantify: 11 of 15 detected K+ spikes were not accompanied by any 
detectable glucose dip. These observations are consistent with the idea that a tissue barrier 
prevents SD-induced transient detection by microdialysis. 
With the retrodialysis of DEX, SD-induced K+ and glucose transients were reliably 
quantified 2 h, 5 days, and 10 days after probe insertion (Figures 4-4 through 4-6). This work is 
our first extension of DEX enhanced microdialysis to K+ and glucose transients, to the rat cortex, 
and to 10 days after probe insertion. We attribute the enhanced transient detection to DEX’s 
ability to prevent ischemia, cell loss, gliosis, and barrier formation at the probe track. A key 
finding of the present study is that the beneficial effects of DEX persisted to 10 days after probe 
insertion even though we stopped retrodialysis of DEX on day 5. 
With the retrodialysis of DEX, however, the amplitude of the K+ transients decreased 
systematically day-to-day (Figure 4-7). First, the amplitudes decreased in response to each 
consecutive needle prick: as mentioned above, this is likely because we repetitively pricked the 
same cortical location. Second, there was a statistically significant decrease from 2 h to 5 days; 
however, there was no further significant decrease from 5 to 10 days. The amplitude of the 
glucose transients exhibited similar declining trends but these were not statistically significant 
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(Figure 4-7). Overall, these day-to-day declines might be an indication that the tissue next to the 
probe becomes more tolerant of SD over time. Brain tissue depends on the vasculature for 
moment-to-moment delivery of glucose and oxygen to meet the energy demands of 
repolarization after SD.64 Retrodialysis with DEX reinstates blood flow to the probe track at 5 
days following insertion31 and Figure 4-8 documents that this persists to 10 days. We speculate, 
therefore, that the declining response amplitudes, especially of the K+ transients, reflect an 
improvement in the health status of the tissue at the probe track. 
Furthermore, we found no evidence of inherent probe failure during this work. During a 
10-day in vitro test, recovery for K+ and glucose remained constant (Table 4-S1). During in vivo 
procedures, all probes maintained consistent flow without evidence of clogging, increased flow 
resistance, or other flow problems. Moreover, there were no statistically significant differences 
among the basal glucose and K+ levels, measured just prior to the onset of the needle prick 
procedures, regardless of postinsertion time or inclusion of DEX. For this reason, we conclude 
that the key factor determining the ability to detect SD-induced transients by microdialysis is the 
status of the tissue adjacent to the probe: the probes themselves show no signs of failure over the 
course of our 10 day studies. 
Although this work was conducted in animals, our eventual goal is clinical translation. 
We hypothesize that the combination of rsMD with DEX-enhanced microdialysis has the 
potential to impact clinical microdialysis in important ways. Traditional clinical microdialysis 
has been previously performed in TBI patients for 10 days with a microdialysis sampling time of 
1 h and without DEX or any other strategy to mitigate the consequences of the probe 
insertion.156, 157 A correlation was found between dialysate glucose levels during the first 50 h of 
microdialysis and patient outcome.157 However, no correlation was found 2–10 days after probe 
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insertion. This latter observation is perplexing, because ECoG detects SD in TBI patients well 
beyond 50 h.16, 69, 73, 155 Although it remains to be seen, we are hopeful that the combination of 
rsMD with DEX retrodialysis will offer enhanced microdialysis monitoring capabilities for 
patients at risk of secondary injury by SD. 
4.4 METHODS 
4.4.1 Reagents and Solutions 
All solutions were prepared with ultrapure water (Nanopure; Barnstead, Dubuque, IA). 
Artificial cerebrospinal fluid (aCSF) contained 142 mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 
mM MgCl2, and 2.0 mM NaH2PO4, adjusted to a pH 7.4. Dexamethasone sodium phosphate 
(APP Fresenius Kabi USA, LLC, Lake Zurich IL) was diluted in aCSF. The microdialysis 
perfusion fluids were filtered with Nalgene sterile filter units (Fisher, Pittsburgh, PA; PES 0.2 
μm pores). Glucose oxidase (GOx, 100–200 units/mg) and horseradish peroxidase (HRP, ≥250 
units/mg) were obtained from Sigma-Aldrich. The ferrocene solution contained 1.5 mM 
ferrocenecarboxylic acid, 1 mM EDTA, 150 mM sodium chloride and 100 mM sodium citrate 
and was filtered before use with 0.1 and 0.02 μm pore size filters. 
4.4.2 Microdialysis Probes, Surgical Procedures, and Experimental Protocol 
Concentric style microdialysis probes were built in-house with hollow fiber membranes 
(13 kDa MWCO, Specta/Por RC, Spectrum, Ranco Dominguez, CA), 4 mm in length and 280 
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μm in outer diameter. Fused silica capillaries (75 μm I.D., 150 μm O.D., Polymicro 
Technologies, Phoenix, AZ) were used for the inlet and outlet lines. Prior to use, probes were 
soaked in 70% ethanol and then flushed and immersed in aCSF (or aCSF with DEX) for several 
hours prior to implantation into the brain. Prior to insertion, the probe inlet was connected to a 1 
mL gastight syringe driven by a microliter syringe pump (Harvard Apparatus, Holliston, MA) at 
a perfusion rate of 1.67 μL/min. The probe outlet (50 cm long) was connected to the K+ ISE 
detector. 
Rats (male, Sprague–Dawley, 250–350g, Charles River, Raleigh, NC) were anesthetized 
with isoflurane (5% induction, 2.5% maintenance), placed in a stereotaxic frame (David Kopf 
Instruments, Tujunga, CA), and adjusted to flat skull151 for probe insertion. Aseptic technique 
was used throughout. The microdialysis probe was lowered at a 51° angle into the cortex using 
the coordinates 4.2 mm posterior to bregma, 1.5 mm lateral to midline, and 4 mm below dura: 
the entire active portion of the probe came to rest in the cortex. For the 2 h study, the rats (n = 8 
per group) remained under anesthesia for the duration of the experiment and responses to needle 
pricks were monitored beginning 2 h after probe insertion. To perform the needle pricks, a 
second hole was drilled through the skull ipsilateral to the probe, just anterior to bregma 
(approximately 4.5 mm from the probe). The surface of the cortex was manually pricked with the 
tip of an 18-gauge hypodermic needle. Three pricks, 30 min apart, were performed per animal. 
For the 5 and 10 day experiments (n = 5 per group), the probes were inserted as described above 
and secured with bone screws and acrylic cement. The incision was closed with sutures, 
anesthesia was removed, and the rats were housed in a Raturn Microdialysis Bowl (MD-1404, 
BASI, West Lafayette, IN) with continuous perfusion of the microdialysis probe at 1.67 μL/min. 
When used, the concentration of DEX was 10 μM for the first 24 h and then 2 μM for the next 5 
 79 
days.31, 35 After 5 or 10 days the rats were reanesthetized 1 h prior to recording responses to 
needle pricks. 
4.4.3 Potassium and Glucose Detection 
The K+ ISE electrode and poly(dimethyl)siloxane (PDMS) microfluidic system have been 
described previously.77 Briefly, a miniaturized K+ ISE was made in-house. A membrane 
containing 2 mg potassium ionophore, 0.2 mg potassium tetrakis(4-chlorophenyl)borate, 150.0 
mg bis(2-ethylhexyl) sebacate, and 66 mg poly(vinyl chloride) (PVC) dissolved in 
tetrahydrofuran (reagents from Sigma-Aldrich) was cast over a segment of 
perfluoroalkoxyalkane tubing (PFA, IDEX Health Sciences, 360 μm O.D. and 150 μm I.D.). The 
electrode was assembled with an internal Ag/AgCl reference and aCSF filling solution. The 
potential of the K+ ISE was measured against an external Ag/AgCl reference electrode using 
custom electronics built in-house. The K+ ISE and external reference electrode were inserted into 
a PDMS chip fabricated with soft lithography, as shown in Figure 4-1. The total internal volume 
of the PDMS chip is approximately 700 nL. Connections to and from the PDMS chip were made 
with 0.15 mm and 0.13 mm ID FEP tubing, respectively. 
The rapid sampling microdialysis (rsMD) system has been described previously.75 
Briefly, the dialysate enters a custom built sampling valve (Valco, Switzerland) with two 100 nL 
internal sampling loops. A standard HPLC pump (flow rate: 200 μL/min) mixed ferrocene 
solution with the dialysate and injected the mixture at 30 s intervals into one of two paths, both 
of which contain dual enzyme reactors in-line with a 3 mm glassy carbon disk electrode. The 
enzyme reactor contained two 6 mm-diameter membranes (0.025 μm pores, Millipore) loaded 
with glucose oxidase (1 mg/mL) or horseradish peroxidase (0.5 mg/mL). The reduction of the 
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ferrocenium ion was measured at 0 V with a three-electrode system with a Ag/AgCl reference 
electrode (UniJet, BASi, USA) and custom-built electronics. 
4.4.4 Data Analysis 
The rsMD data were analyzed with previously published algorithms159 and converted to 
concentration with postexperiment calibrations. In Figures 4-2 through 4-6, the K+ and glucose 
recordings were time-aligned to t0 (Figure 4-1) to account for the travel time to and between the 
sensors. At the 1.67 μL/min flow rate it takes approximately 4 min, t1, for the sample to travel to 
the K+ sensor and an additional 7 min, t2, to travel to the glucose detector (Figure 4-1). The K+ 
spikes were used to confirm SD at the probe site: if there was no K+ spike the needle prick was 
repeated (see discussion of Figure 4-S1). A 10 min baseline prior to the expected glucose 
response was used to calculate a threshold for a detectable glucose signal, defined as 3× the noise 
of the 10 min baseline. If the glucose level dropped below the threshold in the next 15 min it was 
included as a detectable response (see Figure 4-S4). Only detectable glucose responses were 
included in the data analysis and figures. A K+ threshold was calculated in a similar manner 
using the signal recorded for 2 min prior to needle pricks. 
4.4.5 Immunohistochemistry and Fluorescence Microscopy 
The procedures for immunohistochemistry and fluorescence microscopy are described in 
our previous papers.30, 31, 105 Rats were deeply anesthetized with isoflurane (2.5% by volume O2) 
and perfused transcardially with 200 mL 0.01 M phosphate-buffered saline (PBS), pH 7.4, 
followed by 160 mL of 4% paraformaldehyde, and then with 50 mL of a solution containing 
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commercially available (Molecular Probes) 100 nm fluorescent beads (1:1000 dilution PBS). The 
entire brain was quickly removed and further fixed in 4% paraformaldehyde for 24 h at 4 °C 
before being equilibrated in a 30% sucrose solution at 4 °C for 24 h. The brain was then frozen in 
2-methylbutane in a bath of liquid nitrogen to prevent freeze fracturing. The tissue containing the 
probe track was cut to 20-μm sagittal sections (n = 3, 3 slides per animal). Free floating sections 
were rinsed in PBS, three times (10 min each), then blocked with 5% goat serum in PBS 
containing 0.1% Triton X-100 for 1 h at room temperature and subjected to 
immunohistochemical staining. The sections were incubated overnight at 4 °C with the primary 
antibody antiglial fibrillary acidic protein (GFAP; 1:100; #Z033401, DAKO Agilent 
Technologies). As a negative control, PBS was used instead of the primary antibody. Sections 
were then washed with PBS (5 min) and incubated in a secondary solution consisting of 5% goat 
serum, 0.1% Triton X-100, and antibody (1:500 goat anti-rabbit Alexa 568, Invitrogen, Carlsbad 
CA) for 2 h at room temperature. Sections were then rinsed with PBS for 10 min before being 
coverslipped with Fluoromount-G (Southern Biotech, Birmingham AL). Sections were imaged 
using fluorescent microscopy (FluoView 1000, Olympus, Inc., Tokyo, Japan) at 20× 
magnification. 
Tissue images were processed and analyzed with the Metamorph/Fluor 7.1 software 
package (Universal Imaging Corporation; Molecular Devices). Quantitative analysis was based 
on individual sections containing the microdialysis probe track in the ipsilateral region. Sections 
from the contralateral region (nonimplanted control tissue) were treated in identical fashion to 
the ipsilateral region. The fluorescence intensities of GFAP and blood flow were determined by 
setting threshold values; the total number of pixels was expressed as the percent of fluorescence 
in the region of interest.33 Samples were compared to a nonimplanted region of the tissue slice. 
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4.4.6 Statistics  
IBM Statistical Package for the Social Sciences (SPSS) 22 software was used for all 
statistical analysis. For all tests, a p < 0.05 was used for statistical significance. 
4.5 SUPPORTING INFORMATION 
 
Table 4-S1. 
In vitro probe recovery (mean ± S.E.) was consistent when probes were continually perfused and stored in aCSF for 
10 days (n = 3 probes). There is no significant difference between the three time points for either K+ or glucose 
(ANOVA, repeated measures). 
 
 
Figure 4-S1. 
Representative data showing SD induction with no K+ spike or glucose dip. The probe was inserted at time 0. The 
vertical black lines mark 5 SD inductions. Both 1 and 2 were not detected, meaning no change in K+. Approximately 
11% of SD inductions were not detected by the microdialysis probe and thus were not included in the data analysis. 
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Needle pricks 3, 4, and 5 were measured by the probe. An additional feature that was commonly observed is the 
decline in basal glucose following multiple SD. Note there are noise spikes in the K+ signal prior to and after the 
first needle prick and also in the middle of the third SD. The noise spike during the third SD was removed for clarity 
of the corresponding glucose dip. 
 
 
Figure 4-S2. 
Overall trace of an acute study in which the rat died approximately 1 hr after the first needle prick. The first vertical 
black line represents the needle prick. The second vertical black line marks the sudden death of the animal. Probe 
inserted at time zero. 
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Figure 4-S3. 
Data presented in the manuscript are depicted as changes in K+ and glucose. The area under the curve (AUC) was 
also analyzed for each SD response. The A) maximum changes in concentration and B) AUC have similar trends for 
the 5 groups analyzed. 
 
 
Figure 4-S4. 
Characterization of a significant change in glucose. A 10 minute baseline was established prior to the SD (time 
zero). The baseline was used to create a threshold signal to noise ratio, defined as three times the baseline noise 
level. If the glucose signal drops below the threshold (blue line above) in the 15 minutes post SD it was included as 
a detectable glucose signal and was used in the figures and calculations. Figure A is an example of an undetectable 
signal, obtained from the first needle prick of a probe perfused with aCSF for 5 days. Figure B is an example of a 
detectable signal, obtained from the third needle prick of a probe perfused with DEX for 10 days (days 1-5 were 
DEX and days 5-10 were aCSF). 
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5.0  CONCLUSIONS 
The results presented in this dissertation confirm dexamethasone retrodialysis mitigates 
the tissue response to the probe insertion and enhances long-term neurochemical sampling from 
the rat brain. 
Our studies agree with previous observations that inserting a microdialysis probe into the 
brain tissue results in a penetration injury and ensuing tissue response.22-35 The progression of the 
tissue response creates a time-dependent neurochemical disruption in the surrounding area.36-40   
This disruption hinders the ability of the probe to provide an accurate representation of the 
chemical changes occurring in the undisturbed tissue.  
 Our studies show that perfusing dexamethasone (DEX), a glucocorticoid anti-
inflammatory agent, through the microdialysis probe mitigates the tissue response and preserves 
the neurochemical sampling for up to 10 days after probe insertion. The efficacy of DEX appears 
to be due to its anti-inflammatory actions rather than any direct neurochemical impact. 
Histochemical analysis confirmed DEX suppresses microglia activation, reinstated blood flow, 
and prevented the formation of a glial barrier around the microdialysis probe track.35 
Additionally, histochemical markers for dopamine terminals appeared normal at both 24 h and 5 
days after probe insertion regardless of the perfusion fluid containing DEX or not.34, 35  
 We first evaluated the benefits of DEX retrodialysis by using fast scan cyclic 
voltammetry to measure evoked dopamine release in the rat striatum next to and at the outlet of 
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microdialysis probes. The probe insertion injury created a gradient of dopamine release around 
the microdialysis probe, resulting in evoked responses being undetectable at the probe outlet 
without the aid of an uptake inhibitor. However, combining DEX retrodialysis with a 5-day 
postimplantation wait period reinstated normal evoked dopamine activity next to the probe and 
brought the responses at the probe outlet into quantitative agreement with the in vivo responses. 
Previous studies found that uptake inhibition increased the in vivo probe recovery of dopamine 
due to a zone of disrupted tissue adjacent to the probe.22-24, 40, 58, 119, 60, 59  The quantitative 
agreement between the responses in the dialysate and responses next to the probe after 5 days 
with DEX suggests the zone of disrupted tissue is no longer present.  
Our second study confirmed the microdialysis enhancement achieved with DEX is 
transferable to the rat cortex, to monitoring K+ and glucose transients following induced 
spreading depolarization, and to 10 days after probe insertion. The initial insertion of the 
microdialysis probe caused a spreading depolarization, supporting prior evidence of the tissue 
disruption during probe insertion. When comparing responses 2 h and 5 days after probe 
insertion, without DEX the K+ responses decreased and the glucose responses became essentially 
undetectable after 5 days. However with DEX glucose transients were quantifiable at 2 h, 5 days, 
and 10 days after probe insertion. In the 10 day study DEX was removed from the perfusion fluid 
after 5 days, thus the benefits of DEX outlast the retrodialysis itself. This is significant as it is 
ideal to use the minimum amount of an exogenous agent while still maintaining the anti-
inflammatory effects. While our studies have established the anti-inflammatory enhancement of 
microdialysis using DEX, it is important to note that other strategies including the choice of the 
anti-inflammatory agent, dose, and duration are available for future studies.      
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5.1 FUTURE DIRECTIONS 
The future of dexamethasone enhanced microdialysis has the potential to significantly 
impact long-term microdialysis studies for both animal models and human patients. Mitigating 
the tissue response with the retrodialysis of an anti-inflammatory agent is a simple and effective 
method that can be easily translated to other microdialysis studies. Microdialysis is an 
exceptionally versatile technique, thus enhancing microdialysis with dexamethasone extends 
beyond the analytes and research areas investigated thus far. 
The work presented herein focused on using dexamethasone as the anti-
inflammatory agent to mitigate the tissue response to the microdialysis probe insertion. We did 
not encounter any neurochemical perturbations associated with the use of a steroidal anti-
inflammatory agent. However, steroids are known to be active in the brain, thus depending on 
the application, future investigations may be interested in non-steroidal alternatives.  
The use of microdialysis in animal models has vastly contributed to our understanding 
of the neurochemistry in the living brain. Currently, most microdialysis studies rely on 
repeated probe insertions or multiple animals to evaluate the neurochemical changes that occur 
over time. Using dexamethasone enhanced microdialysis will provide future investigations 
with extended monitoring from a single animal. Our observations have shown that 5 days of 
dexamethasone retrodialysis enhances microdialysis sampling for up to 10 days after probe 
insertion. It will be important for future investigations to extend this time frame and explore 
the mitigation of the initial tissue response with 5 days of dexamethasone and its impact on 
microdialysis studies weeks or months after the initial probe insertion. 
In addition to animal models, microdialysis is exceptionally beneficial for clinical 
applications. Microdialysis is currently used to monitor patients with traumatic brain injury to 
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identify episodes of spreading depolarization, a form of secondary brain injury. Clinical 
microdialysis studies are currently research based, thus the data obtained are not used for 
patient diagnosis or care. However, investigators are interested in using microdialysis not 
only to identify the frequency and duration of spreading depolarization, but also to develop 
targeted treatment methods. Events of spreading depolarization occur in approximately 60% of 
traumatic brain injured patients, contributing to the heterogeneity of this disease. Real time 
monitoring of spreading depolarization would allow not only for personalized treatment plans 
but also evaluation of the therapeutic effect during treatment. Our work has shown that 
dexamethasone enhances the microdialysis sampling K+ and glucose transients following 
spreading depolarization in an animal model for up to 10 days after probe insertion. Translating 
this work into clinical applications will improve the identification of spreading depolarization, 
and aid in the understanding and treatment of this complex disease.   
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